US Pat. No. 11,110,140

MEDICINAL FOOD PRODUCTS AND METHODS FOR PRODUCING SAID PRODUCTS


1. A method for producing a medicinal food product comprising the steps of:a. homogenously mixing a first food product with cannabis and lecithin to prepare a cannabis/first food product/lecithin mixture;
b. heating the cannabis/first food product/lecithin mixture to 100° F.-200° F.;
c. sonicating the cannabis/first food product/lecithin mixture;
d. mixing the cannabis/first food product/lecithin mixture with a second food product to create a cannabis/first food product/lecithin/second food product;
e. freezing the cannabis/first food product/lecithin/second food product for 10 hours-48 hours;
f. dehydrating the cannabis/first food product/lecithin/second food product for 10 hours-48 hours;
g. dividing the cannabis/first food product/lecithin/second food product into containers; and
h. vacuum sealing the containers with oxygen absorbers to produce containers of cannabis/first food product/lecithin/second food product.

US Pat. No. 11,112,714

TONER

CANON KABUSHIKI KAISHA, ...


1. A toner, comprising:a toner particle; and
an external additive comprising spherical silica particles having a circularity of at least 0.80 and hydrotalcite particles, wherein
a ratio Db/Da of a number average particle diameter Db (nm) of the hydrotalcite particles to a number average particle diameter Da (nm) of the spherical silica particles is 7.5 to 30.0,
the number average particle diameter Da (nm) of the spherical silica particles is 10 to 40, and{Ga×(1?Ka/100)}/{Gb×(1?Kb/100))?0.050

where Ga is a content of the spherical silica particles with respect to 100 parts by mass of the toner particle, Gb is a content of the hydrotalcite particles with respect to 100 parts by mass of the toner particle, Ka is a fixing ratio (%) of the spherical silica particles on a surface of the toner particle and Kb is a fixing ratio (%) of the hydrotalcite particles on the surface of the toner particle.

US Pat. No. 11,110,141

HERBAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF URINARY INCONTINENCE AND OVERACTIVE BLADDER

Rox IP Pty Ltd.


1. An herb for treating or reducing the symptoms of urinary incontinence or overactive bladder comprising effective amounts of:(i) a Crateva nurvala extract preparation;
(ii) an Equisetum arvense extract preparation; and
(iii) a Lindera aggregata extract preparation;
wherein the herb-containing composition is formulated as an oral dosage unit whereby the oral dosage unit is in a form selected from a tablet, capsule or caplet.

US Pat. No. 11,110,142

KAMPO MEDICINE FOR IMPROVING COGNITIVE FUNCTION IN ALZHEIMER-TYPE DEMENTIA OR MILD COGNITIVE IMPAIRMENT AND TREATING AT LEAST ONE DISEASE FROM THE GROUP CONSISTING OF OVERACTIVE BLADDER, CONSTIPATION, AND CHRONIC KIDNEY DISEASES COMPLICATED BY THEM WITH O


1. A method for treating multimorbidity in a patient, comprising:administering to the patient one kampo combination drug consisting of a drug combination of:
(i) orengedokuto, formulated from dried crude drugs Coptis Rhizome, Scutellaria Root, Phellodendron Bark, and Gardenia Fruit, wherein the mixed weights of the dried crude drugs in a daily dose for an adult are 1.5 g to 2.0 g for Coptis Rhizome, 3.0 g for Scutellaria Root, 1.5 g to 3.0 g for Phellodendron Bark, and 2.0 g to 3.0 g for Gardenia Fruit; and
(ii) ryokeijutsukanto, formulated from dried crude drugs Poria Sclerotium, Atractylodes Lancea Rhizome or Atractylodes Rhizome, Cinnamon Bark, and Glycyrrhiza, wherein the mixed weights of the dried crude drugs in a daily dose for an adult are 4.0 g to 6.0 g for Poria Sclerotium, 2.0 g to 3.0 g for Atractylodes Lancea Rhizome or Atractylodes Rhizome, 3.0 g to 4.0 g for Cinnamon Bark, and 1.0 g to 2.0 g for Glycyrrhiza,
wherein the one kampo combination drug relieves and treats at least one disease selected from the group consisting of: an overactive bladder, constipation, and chronic kidney disease.

US Pat. No. 11,110,143

METHOD FOR PREPARING CITRUS-DERIVED COMPLEX PREBIOTIC AGENT AND USE OF THE SAME

ZHEJIANG UNIVERSITY, Han...


1. A method for preparing a citrus-derived complex prebiotic composition, comprising the following steps:(1) subjecting segments of a citrus fruit to a soaking treatment with a certain volume of an acid and water solution having a concentration greater than 0.05 g/100 mL, until membranes of the segments of the citrus fruit become gel-like, and filtering the segments of the citrus fruit to obtain an acid-treated water;
(2) transferring the acid-treated segments of the citrus fruit to a certain volume of an alkali and water solution having a concentration greater than 0.1 g/100 mL, subjecting the acid-treated segments of the citrus fruit to soaking treatment with the alkali and water solution until the membranes of the segments of the citrus fruit are dissolved, and performing filtering to obtain an alkali-treated water; and
(3) adjusting the pH of the alkali-treated water with the acid-treated water to a pH of 4-7, and performing filtering to obtain a complex prebiotic composition wherein the alkali is selected from the group consisting of NaOH, Na2CO3, KOH, K2CO3, Mg(OH)2, and Ca(OH)2, the acid is selected from the group consisting of hydrochloric acid, citric acid, oxalic acid, tartaric acid, malic acid, and lactic acid, and the citrus fruit is selected from the group consisting of Citrus reticulate Blanco, pomelo, orange, grapefruit, and lemon.

US Pat. No. 11,111,428

THERMALLY-STABLE, NON-PRECIPITATING, HIGH-DENSITY WELLBORE FLUIDS

Halliburton Energy Servic...


1. A system comprising:a wellbore that penetrates a subterranean formation; and
a treatment fluid comprising:(A) a base fluid; and
(B) a water-soluble salt, the salt comprising:(i) a cation selected from ammonium, phosphonium, quaternary amines, poly-quaternary amines, and rare earth metals; and
(ii) an anion, wherein the anion is selected from phosphotungstate, silicotungstate, and silicomolybdate.



US Pat. No. 11,110,144

WOLFBERRY GLYCOPEPTIDE COMPOSITION AND METHODS FOR PREPARING AND USING THE SAME

Shanghai Institute of Org...


1. A method for preparing a glycopeptide composition, comprising:(a) soaking fruit of wolfberry in water and centrifuging to remove precipitated solids to obtain a first extract solution;
(b) heating the first extract solution to provide a flocculation in the first extract solution, and centrifuging the first extract solution to remove the flocculation to obtain a second extract solution, wherein the second extract solution has a light transmittance at 50% or higher at 400 nm; and
(c) treating the second extract solution with an ultrafiltration membrane, obtaining a cut-off solution with a molecular weight cutoff of the ultrafiltration membrane, concentrating, and drying the cut-off solution to obtain a glycopeptide composition,
wherein the flocculation is formed by agglomerating insoluble substances in the first extract solution into precipitates, the molecular weight cutoff of the ultrafiltration membrane is in a range of 1000 Da to 2000 Da, and each of the steps (1) to (3) is conducted in water only.

US Pat. No. 11,111,173

LITHIUM CONTAINING GLASSES

CORNING INCORPORATED, Co...


1. A glass article comprising, on an oxide basis:from greater than or equal to 65 mol% to less than or equal to 74 mol% SiO2;
from greater than or equal to 7 mol% to less than or equal to 12 mol% Al2O3;
from greater than or equal to 5 mol% to less than or equal to 16 mol% B2O3;
from greater than or equal to 0 mol% to less than or equal to 4 mol% Na2O;
from greater than or equal to 0 mol% to less than or equal to 5 mol% P2O5;
from greater than or equal to 5 mol% to less than or equal to 11 mol% Li2O; and
from greater than or equal to 0.5 mol% to less than or equal to 6.5 mol% divalent cation oxides, wherein a molar ratio of Al2O3:(R2O+RO) is greater than or equal to 0.9, where R20 is a sum of alkali metal oxides in mol% and RO is a sum of divalent cation oxides in mol%.

US Pat. No. 11,110,145

COMPOSITION FOR PROTECTING CELL FROM OXIDATIVE STRESS COMPRISING GREEN TEA EXTRACT WHICH HAS MODIFIED AMOUNTS OF INGREDIENTS

AMOREPACIFIC CORPORATION,...


1. A method for protecting cells from oxidative stress, comprising administering a composition comprising as an active ingredient a green tea extract containing 5 to 25% by weight of (?)-gallocatechin gallate (GCG) and 7 to 15% by weight of (?)-epigallocatechin gallate (EGCG) based on the total weight of the composition to a subject in need thereof,wherein the total content of the GCG and EGCG in the extract is 40% by weight or less based on the total weight of the composition, and
wherein the GCG and the EGCG are contained in the green tea extract in a weight ratio of 1:1 to 1:2.5.

US Pat. No. 11,110,146

METHODS FOR REDUCING PLATELET AGGREGATION AND TREATING CARDIOVASCULAR DISEASE AND OTHER MEDICAL DISORDERS

Paradise Health, Inc., W...


1. A method of treating cardiovascular disease in a patient, comprising orally administering to a patient in need thereof an effective amount of a therapeutic composition comprising ground seed of Aframomum melegueta or an extract thereof, to treat the cardiovascular disease, wherein there is a reduction in the incidence of platelet aggregation caused by arachidonic acid, there is a reduction in the incidence of platelet aggregation caused by adenosine diphosphate, and there is a reduction in the incidence of platelet aggregation caused by collagen.
US Pat. No. 11,110,147

COLLAGEN HYDROLYSATES AS A BENEFICIAL PREBIOTIC AND THEIR EFFECT ON JOINT INFLAMMATION AND OSTEOARTHRITIS

ROUSSELOT B.V UNIVERSITY ...


1. A method of administering a prebiotic to a subject comprising administering to the subject a prebiotic composition comprising hydrolyzed collagen peptides, wherein the hydrolyzed collagen peptides are type 1 hydrolyzed collagen peptides (hCol1) originating from bovine, or type 2 hydrolyzed collagen peptides (hCol2) originating from porcine, wherein the hCol1 have a mean molecular weight between about 1800 Da and about 3500 Da and the hCol2 have a mean molecular weight between about 1300 Da and about 3000 Da.
US Pat. No. 11,109,892

METHODS AND DEVICES FOR CONDUIT OCCLUSION

Femasys Inc., Suwanee, G...


1. A method for delivering a fluid composition to one fallopian tube in a mammal, comprising,a) positioning at the cornua of one fallopian tube of a mammal, an end structure of a catheter so that a delivery end of the catheter is located within the uterine cornua and is at or near a tubal ostium, wherein the end structure maintains the delivery end in the uterine cornua and aids in localized delivery of the fluid composition;
b) delivering an effective amount of the fluid composition through and out the delivery end of the catheter so that at least a portion of the fluid composition is delivered to the fallopian tube.

US Pat. No. 11,110,148

SILK FIBROIN MATERIALS AND USE THEREOF

Trustees of Tufts College...


1. A three-dimensional body comprising silk fibroin having interconnected pores, wherein the pores have an average diameter between 50 microns and 100 microns, and wherein total porosity of the three-dimensional body is at least 80%.
US Pat. No. 11,111,177

MANUFACTURING A BINDER WITH HIGH ? BELITE CONTENT

HConnect 2 GmbH, Heidelb...


1. A method for manufacturing a binder with ? belite content of at least 20% by weight comprising the steps:a) providing a starting material by selecting one raw material having a Ca/Si molar ratio of 1.5 to 2.5 or by mixing two or more raw materials to obtain a starting material with the Ca/Si molar ratio of 1.5 to 2.5;
b) hydrothermal treatment of the starting material produced in step a) in an autoclave at a temperature of 100 to 300° C. and a retention time of 0.1 to 24 h, wherein the water/solid ratio is from 0.1 to 100 to provide an intermediate product;
c) annealing the intermediate product obtained in step b) in a flash calciner at 620 to 630° C., wherein the retention time is 1-30 seconds.

US Pat. No. 11,111,433

TRANSPARENT FLUORESCENT SIALON CERAMIC AND METHOD OF PRODUCING SAME

NATIONAL UNIVERSITY CORPO...


1. A fluorescent sialon ceramic consisting of:a sialon phosphor in the form of a sintered bulk body, the sialon phosphor consisting of a matrix formed of ?-sialon represented by the formula (Si,Al)6(N,O)8, and a luminescent center element,
wherein the linear transmittance of visible light of the sintered bulk body is 11% or greater at a wavelength of 800 nm as measured with respect to a test specimen of the sintered bulk body having a thickness of 100 ?m.

US Pat. No. 11,110,149

METHOD FOR PREDICTING AND MONITORING THE EFFICACY OF LOW-DOSE IL-2 AND HYDROXYCHLOROQUINE THERAPY IN AUTOIMMUNE DISEASES AND ITS LONG-TERM USE IN AUTOIMMUNE-RELATED CONDITIONS

KSL BIOMEDICAL INC., Wil...


1. A method of inhibiting or treating systemic lupus erythematosus (SLE) in a subject in need thereof, the method consisting of administering to the subject a therapeutically effective low-dose amount of interleukin-2 in combination with a therapeutically effective amount of hydroxychloroquine, thereby inhibiting or treating SLE in the subject.
US Pat. No. 11,111,178

RENEWABLE ADMIXTURES FOR CEMENTITIOUS COMPOSITIONS

THE BOARD OF TRUSTEES OF ...


1. A composition, comprising:a hydraulic cementitious material;
a hydroxyl containing compound selected from the group consisting of water soluble polyhydroxy aromatic compounds, wherein the hydroxyl containing compound is present in an amount of from 0.1% to 3% by weight, based on the total weight of the cementitious material, and
a particulate material and optionally a water soluble silicate-containing material that interacts with the hydroxyl containing compound,
wherein the particulate material comprises nanoparticles present in an amount of from 0.2% to 5% by weight, based on the total weight of the cementitious material and the hydroxyl containing compound.

US Pat. No. 11,111,434

LIGHT EMITTER, METHOD FOR PRODUCING LIGHT EMITTER, AND BIOLOGICAL SUBSTANCE LABELING AGENT

MURATA MANUFACTURING CO.,...


1. A light emitter for labeling a biological substance, the light emitter comprising:nanoparticles composed of a compound semiconductor that contains an Ag compound, an In component, and a Se component,
wherein the compound semiconductor is a light-emitting material that emits light at an emission intensity having a peak wavelength within a range between 700 nm and 1400 nm, and
wherein a mixing ratio of the In component to the Ag component is between 2 and 3 in terms of molar ratio, such that the light-emitting material is constructed to emit light at the emission intensity having the peak wavelength that is 85 nm or less in half-value width.

US Pat. No. 11,110,150

COMPLEXES OF IL-15 AND IL-15RALPHA AND USES THEREOF

NOVARTIS AG, Basel (CH) ...


1. A method of recombinantly producing a human IL-15 and a human IL-15Ra complex, comprising:(a) culturing a cell expressing a human IL-15 encoded by a nucleic acid sequence with at least 95% identity to nucleic acid residues 1 to 489 of SEQ ID NO:2; and a human IL15Ra encoded by: (i) a nucleic acid sequence with at least 95% identity to nucleic acid residues 1 to 804 of SEQ ID NO:5; or (ii) a nucleic acid sequence with at least 95% identity to nucleic acid residues 1 to 615 of SEQ ID NO:6 and
(b) purifying the human IL-15 and human IL-15Ra complex,

wherein the cell expresses at least 150 ng/million cells of human IL-15 per day when cultured in serum-free media.
US Pat. No. 11,111,179

NON-FIRED MONOLITHS

Katholieke Universiteit L...


1. A method for manufacturing an inorganic polymer object from a precursor that comprises a gibbsite-containing residue or a thermally processed gibbsite-containing residue of the Bayer process, the precursor comprising less than 0.01 wt % silica fume, the method comprising:alkaline-activating the precursor;
mixing the precursor;
shaping the precursor after the mixing; and
hydrothermally curing the precursor, after the shaping, at a temperature from 70° C. to 350° C. and under a pressure greater than 1 bar and less than 500 bar.

US Pat. No. 11,110,151

COMPOSITION AND METHOD FOR REDUCING HYPOGLYCEMIA EVENTS IN DIABETES TREATMENT

MannKind Corporation, We...


1. A method of treating diabetes comprising, administering to a patient with diabetes, exhibiting hypoglycemic events, a pharmaceutical composition comprising an inhalable dry powder comprising insulin and fumaryl diketopiperazine to replace rapid acting insulin analog used at mealtime, wherein the patient is not taking basal insulin and the pharmaceutical composition upon inhalation mimics native insulin release during a meal and significantly reduces the rate of hypoglycemic events in the patient who is subject to severe hypoglycemia with rapid acting insulin analog treatment.
US Pat. No. 11,111,180

BUILDING ELEMENTS MADE FROM BINDERS HARDENING BY COMBINED HYDRATION AND CARBONATION

HConnect 2 GmbH, Heidelb...


1. A method of manufacturing building elements comprising the steps:providing a binder comprising at least 8% by weight ternesite, at least 15% by weight dicalcium silicate and at least 5% by weight ye'elimite, each with respect to the total binder, as hydraulically reactive phases
mixing the binder with water to form a paste
casting the paste into a shape for the building element
reacting the paste hydraulically to form hydrated phases and to create additional capillary pores, and
carbonation hardening to provide the building element.

US Pat. No. 11,111,436

SOIL ADDITIVES FOR PROMOTING SEED GERMINATION, FOR PREVENTION OF EVAPORATION AND METHODS FOR USE

RHODIA OPERATIONS, Auber...


1. A method of decreasing water evaporation from soil, the method comprising:introducing a bulk additive to a target soil area, wherein the bulk additive is in an aqueous mixture or in a dry or semi-dry form;
wherein the step of introducing the bulk additive to a target soil area comprises applying the bulk additive to the surface of target soil area then mixing the bulk additive into the target soil area at a predetermined depth less than three feet to block the water from migrating toward the soil surface to be susceptible to evaporation.

US Pat. No. 11,110,152

COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING LUNG DISEASE

ARIZONA BOARD OF REGENTS ...


1. A method, comprising: delivering a composition comprising a peptide consisting of KEQCVEMYTD (SEQ ID NO: 4) to a lung cell in a subject, wherein said delivering results in one or more of enhancing SP-A activity in the cell, and treating asthma in the subject.
US Pat. No. 11,111,437

LIQUID CRYSTAL COMPOSITION, OPTICALLY ANISOTROPIC LAYER, OPTICAL LAMINATE, AND IMAGE DISPLAY DEVICE

FUJIFILM Corporation, To...


1. A liquid crystal composition comprising:a liquid crystal compound;
a photo-alignment compound; and
a polymer obtained by polymerizing a monomer having two or more radically polymerizable double bonds and one or more hydroxyl groups,
wherein the photo-alignment compound is a photo-sensitive compound having a photo-reactive group which is subjected to at least one of dimerization or isomerization by the action of light, and
the photo-reactive group has a skeleton of at least one type of derivative or compound selected from the group consisting of cinnamic acid derivations, courmarin derivatives, chalcone derivations, maleimide derivatives, azobenzene compounds, stilbene compounds and spiropyran compounds.

US Pat. No. 11,110,153

MODIFIED FACTOR IX, AND COMPOSITIONS, METHODS AND USES FOR GENE TRANSFER TO CELLS, ORGANS, AND TISSUES


1. A recombinant adeno-associated virus (rAAV) vector comprising a vector genome encapsidated by an AAV capsid, wherein said vector genome comprises an AAV inverted terminal repeat (ITR) and a nucleic add sequence encoding human Factor IX (FIX) protein, wherein said nucleic add sequence encoding human FIX protein is at least 90% identical to SEQ ID NO:10, has a reduced number of CpG di-nucleotides compared to wild-type nucleic add sequence encoding human FIX protein and encodes the same human FIX protein encoded by SEQ ID NO: 10.
US Pat. No. 11,110,154

METHODS AND COMPOSITIONS FOR TREATING HUNTINGTON'S DISEASE

Sangamo Therapeutics, Inc...


1. A method of reducing expression of a mutant Huntingtin (mHtt) gene to reduce or prevent the formation of Htt aggregates in a medium spiny neuron in a subject with Huntington's Disease (HD), the method comprisingadministering to the striatum of the subject a polynucleotide encoding a repressor of a mutant Htt (mHtt) allele, the repressor comprising a zinc finger protein designated 30640, 30645 or 33074, wherein the polynucleotide comprises an adeno-associated virus (AAV) vector administered at 2×1010 vector genomes, wherein the transcription factor repressor reduces mHtt expression by at least 85% in HD neurons in the striatum of the subject and reduces the formation of Htt aggregates in the medium spiny neuron by 20 to 50% as compared to an untreated subject.

US Pat. No. 11,111,183

UNSHAPED PRODUCT FOR REPAIRING GLASS MELTING FURNACES


1. A wet mixture consisting of:an unshaped product comprising, as percentages by weight and for a total of 100%,
A) a set of particles (a) of at least one refractory material other than a glass and a glass-ceramic, and the main constituent(s) of which are alumina (Al2O3) and/or zirconia (ZrO2) and/or silica (SiO2) and/or chromium oxide (Cr2O3),
B) a set of particles (b) of a hot binder chosen from glass-ceramic particles, particles made of a glass and the mixtures of these particles: 2% to 15%, said glass being a noncrystalline material exhibiting a glass transition temperature of less than 800° C., the hot binder not being in the solid state at 1500° C.,
C) a set of particles (c) of hydraulic cement: less than 2%,
D) less than 7% of constituents other than particles (a), (b), and (c), said particles (a) and (b) being distributed, as percentages by weight with respect to the weight of the unshaped product, in the following way:fraction<0.5 ?m: ?1%,
fraction<2 ?m: ?4%,
fraction<10 ?m: ?13%,
fraction<40 ?m: 25%-52%,

the content of the set of particles (a) being the complement, to reach 100%, to the whole content of the particles (b), of the set of particles (c) and of said other constituents, and
water in an amount of greater than 9%, by weight, with respect to the weight of said unshaped product.

US Pat. No. 11,110,155

IMMUNOTHERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

Mercia Pharma, Inc., New...


1. An immunotherapeutic composition for the treatment of Alzheimer's disease comprising:an immunogen comprising a peptide, said peptide comprising an amino acid sequence of 7-15 consecutive amino acid residues of human amyloid beta protein 1-42 conjugated to an immunogenic carrier protein, formulated in a water-in-oil emulsion with an oily adjuvant vehicle comprising squalene, squalane and mannide monooleate, and polyoxyl-40-hydrogenated castor oil, wherein the immunogen is contained within aqueous globules that have a median diameter from about 100 nanometers to about 1 micron;
wherein:
the immunogenic carrier protein is diphtheria toxoid carrier;
the immunogen has a conjugation ratio of moles of peptide per mole of carrier of from about 5:1 to about 30:1;
the oily adjuvant vehicle comprises from about 85% to about 90% squalene and squalane, from about 9% to about 12% mannide monooleate and from about 0.5% to about 0.7% polyoxyl 40-hydrogenated castor oil; and
the peptide comprising the amino acid sequence of human amyloid beta protein is coupled to the immunogenic carrier protein via a spacer.

US Pat. No. 11,110,156

NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED TUMOUR ANTIGEN


1. A nucleic acid molecule comprising:(I) a DNA molecule coding for, from 5 to 3?:
a) a polypeptide coding region, encoding a tumour antigen or an epitope of a tumour antigen;
b) a poly(A) sequence or a polyadenylation signal, and
c) at least one histone stem-loop that encodes a RNA that specifically binds to stem-loop binding protein (SLBP) without a histone downstream element (HDE); or
(II) a RNA molecule comprising, from 5? to 3?:
a) a polypeptide coding region, encoding a tumour antigen or an epitope of a tumour antigen;
b) a poly(A) sequence, and
c) at least one histone stem-loop that specifically binds to SLBP without a HDE.

US Pat. No. 11,110,157

COMBINATION OF VACCINATION AND OX40 AGONISTS


1. A combination kit comprising:(i) a composition comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and
(ii) a composition comprising an OX40 agonist, wherein the OX40 agonist comprises an OX40-binding antibody, or an antigen-binding fragment thereof, or a nucleic-acid encoded an OX40-binding antibody or an antigen-binding fragment thereof.

US Pat. No. 11,110,158

PROSTATE-ASSOCIATED ANTIGENS AND VACCINE-BASED IMMUNOTHERAPY REGIMENS

Pfizer Inc., New York, N...


1. A plasmid vector which comprises a multi-antigen construct encoding two different immunogenic polypeptides, wherein each of the immunogenic polypeptides is encoded by a coding nucleotide sequence on the multi-antigen construct, wherein the multi-antigen construct comprises a separator sequence between the two coding nucleotide sequences, wherein one of the two different immunogenic polypeptides is an immunogenic PSMA polypeptide and the other immunogenic polypeptide is an immunogenic PSA polypeptide, and wherein the immunogenic PSA polypeptide consists of an amino acid sequence selected from the group consisting of:(1) an amino acid sequence consisting of amino acids 27-263 of SEQ ID NO:15;
(2) an amino acid sequence consisting of amino acids 4-240 of SEQ ID NO:17; and
(3) the amino acid sequence of SEQ ID NO:17.

US Pat. No. 11,111,443

PROCESS AND ZEOLITIC CATALYST FOR THE CATALYTIC CRACKING OF UNCONVENTIONAL LIGHT CRUDE OIL TYPE SHALE/TIGHT OIL AND ITS BLENDS WITH VACUUM GAS OIL

INSTITUTO MEXICANO DEL PE...


2. A catalytic system, comprising:a heterogeneous solid acid catalyst based on a formulation with at least one active zeolite comprising Faujasite Y zeolite and a coke selective active matrix;
wherein the active matrix is selected from a group consisting of gamma phase alumina, silica-alumina or silicon oxide, kaolin, aluminum chlorohydrate, or mixtures thereof and avoids the use of phosphate; and
hydrocarbon feedstocks consisting of vacuum gas oil (VGO), conventional vacuum gas oil, hydrotreated vacuum gas oil, unconventional light crude oil, or unconventional light crude oil type shale/tight oil and its blends with conventional vacuum gas oil, in a percentage range of from 0 to 100% by volume of unconventional light crude oil, put in contact with the heterogeneous solid acid catalyst.

US Pat. No. 11,110,159

METHODS FOR INDUCING AN IMMUNE RESPONSE

GLAXOSMITHKLINE BIOLOGICA...


1. A method for inducing an immune response comprising a T cell response in a subject comprising:administration of a chimpanzee adenovirus encoding a Rv1196 related antigen comprising SEQ ID NO: 1, followed by administration of a polypeptide Rv1196 related antigen to the subject, wherein the polypeptide Rv1196 related antigen is provided in a composition which also comprises an adjuvant.

US Pat. No. 11,110,674

METHOD FOR PRODUCING A COMPOSITE FABRIC MATERIAL AND DRIVE BELT COVERED WITH COMPOSITE FABRIC MATERIAL

ContiTech Antriebssysteme...


1. A method for producing a composite fabric material, the composite fabric material comprising a textile integrated in a matrix of elastomeric material, the method comprising:introducing the textile and the elastomeric material into a gap between a band and a cylindrical molding wheel,
molding the textile and the elastomeric material to form the composite fabric material between the band and the cylindrical molding wheel at a temperature below a vulcanization temperature of the elastomeric material,
wherein the band is looped around the molding wheel at a looping angle under a pressure of from 2 to 6 bar, and wherein the textile has over 50% elongation under a tensile stress of 100 N in a longitudinal direction as measured on a textile strip with a width of 5 cm.

US Pat. No. 11,111,444

PROCESS FOR REDUCING NITROGEN CONTENT OF HYDROCARBON FEED

Reliance Industries Limit...


1. A process for reducing the nitrogen content in a hydrocarbon feed comprising nitrogen compounds, the process comprising the following steps:a. mixing the hydrocarbon feed with at least one adsorbent to obtain a mixture;
b. stirring the mixture at a temperature in the range of 25° C. to 80° C. for a pre-determined time period to obtain a resultant mixture;
c. allowing the resultant mixture to settle to separate an upper phase comprising treated hydrocarbon having reduced nitrogen content and a lower phase comprising a complex of nitrogen compounds and the adsorbent; and
d. separating the upper phase from the lower phase to obtain treated hydrocarbon having reduced nitrogen content;

wherein the adsorbent is a mixture of a Lewis acid and a Lewis base;
wherein the Lewis acid is at least one selected from the group consisting of AlCl3, FeCl3, ZnCl2, GaCl3, InCl3, TiCl4, SnCl4, BiCl3 and ZrCl4; and the Lewis base is at least one selected from the group consisting of Al(OH)3, Fe(OH)3 and Zn(OH)2.
US Pat. No. 11,111,189

NON-AQUEOUS ORGANO LIQUID DELIVERY SYSTEMS CONTAINING DISPERSED POLY (ORGANIC ACIDS) THAT IMPROVE AVAILABILITY OF MACRO AND MICRO-NUTRIENTS TO PLANTS


1. A composition comprising a) one or more Poly (organic acids), [P(OA)]s, and/or their salts, b) a Non-aqueous Organo Solvent Delivery System (NOSDS), c) one or more nitrification inhibitors and/or one or more urease inhibitors, and d) one or more members selected from the group consisting of i) one or more fertilizers selected from the group consisting of (1) fertilizer solids and (2) liquid fertilizers and ii) seeds, wherein the NOSDS is the delivery formulation for delivering the one or more [P(OA)]s and/or their salts to said fertilizers and seeds, wherein the NOSDS comprises one or more members selected from the group consisting of i) one or more protic solvents and ii) one or more aprotic solvents, wherein the one or more protic solvents is selected from the group consisting of(1) one or more alcohols selected from the group consisting of C1-10 alcohol,
(2) one or more polyols selected from the group consisting of trimethylol propane, trimethylol ethane, pentaerythritol, sorbitol and sorbitan, glucose, fructose, galactose, and glycerin,
(3) one or more poly(C1-10 alkylene) glycols,
(4) one or more alkylene glycols selected from the group consisting of ethylene glycol, 1,3 propylene glycol, 1,2 propylene glycol, and butylene glycol,
(5) isopropylidene glycerol,
(6) one or more alkylene glycol alkyl ethers selected from, the group consisting of tripropylene glycol methyl ether, tripropylene glycol butyl ether, dipropylene glycol methyl ether and dipropylene glycol butyl ether,
(7) one or more lactates selected from the group consisting of ethyl, propyl, and butyl lactate,
(8) one or more alkanolamine selected from the group consisting of ethanolamine, diethanolamine, dipropanolamine, methyl diethanolamine, monoisopropanolamine and triethanolamine, and
(9) glycerol carbonate,

and wherein the one or more aprotic solvents is selected from the group consisting of(1) dimethyl sulfoxide,
(2) one or more members selected from the group consisting of dialkyl sulfoxide, diary sulfoxide, and alkylaryl sulfoxides having the formula:(a) R1S(O)xR2
wherein R1 and R2 are each independently a C1-6 alkyl group, an aryl group, or C1-3 alkylenearyI group, or R1 and R2 with the sulfur to which they are attached form a 4 to 7 membered ring wherein R1 and R2 together are a C1-6 alkylene group which optionally contains one or more atoms selected from the group consisting of O, S, Se, Te, N, and P in the ring and xi s 1 or 2,

(3) one or more alkylene carbonates selected from the group consisting of ethylene carbonate, propylene carbonate and butylene carbonate,
(4) a polyol capped with acetate or formate wherein the one or more polyol portion is selected from the group consisting of ethylene glycol, 1,3 propylene glycol, 1,2 propylene glycol, butylene glycol, trimethylol propane, trimethylol ethane, pentaerythritol, sorbitol, sorbitan, glucose, fructose, galactose, and glycerin,
(5) one or more alkylene glycol alkyl ether acetates selected from the group consisting of dipropylene glycol methyl ether acetate, tripropylene glycol methyl ether acetate, and tripropylene glycol butyl ether acetate,
(6) isophorone,
(7) one or more alkyl diesters selected from the group consisting of dimethylsuccinate, dimethyl adipate, diethyl glutarate, and dimethyl glutarate,
(8) one or more members selected from the group consisting of dimethylacetamide, dimethylformamide, and dimethyl-2-imidazolidinone,
(9) hexamethylphosphoramide,
(10) 1,2-dimethyloxyethane,
(11) 2-methoxyethyl ether,
(12) cyclohexylpyrrolidone, and
(13) limonene,

wherein said one or more inhibitors is selected from the group consisting of one or more nitrification inhibitors and one or more urease inhibitors, wherein the one or more nitrification inhibitors is selected from the group consisting of (1) 2-chloro-6-trichloromethylpyridine, (2) 4-amino-1,2,4-6-triazole-HCL (3) 2,4-diamino-6-trichloromethyltriazine CL-1580, (4) dicyandiamide, (5) thiourea, (6) 1-mercapto-1,2,4-triazole, (7) 2-amino-4-chloro-6-methylpyrimidine, and (8) dimethyl pyrazole phosphate, and wherein the one or more urease inhibitors is selected from the group consisting of: (1) alkyl thiophosphoric triamides, (2) acetohydroxamic acid and its derivatives, (3) phosphodiamidate, (4) phosphoric triamides, (5) thiophosphoric triamides, and (6) alkylated thiophosphoric triamides, wherein the alkylated thiophosphoric triamides has one or more alkyl groups that independently contain between 1 and 6 carbon atoms and wherein the composition of the NOSDS and [P(OA)]s is substantially free of water.
US Pat. No. 11,110,161

VACCINE FOR PROPHYLAXIS OR TREATMENT OF AN ALLERGEN-DRIVEN AIRWAY PATHOLOGY


1. A method of reducing allergen-driven lung eosinophilia in a subject with asthma, the method comprising the step of infecting the subject's respiratory tract with a live attenuated Bordetella pertussis strain which is deficient in tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT).
US Pat. No. 11,111,190

PROCESS FOR THE DECARBOXYLATIVE KETONIZATION OF FATTY ACIDS OR FATTY ACID DERIVATIVES

RHODIA OPERATIONS, Auber...


1. A process P for the decarboxylative ketonization of fatty acids, fatty acid derivatives or mixtures thereof in liquid phase with metal compounds as catalysts, the process comprising:a) in a first step, elementary metal or a metal compound, said elementary metal or metal compound being selected from the group consisting of iron, iron (II) oxide, a mixed oxide of iron (II) and iron (III), magnesium and magnesium oxide, and at least one fatty acid, at least one fatty acid derivative or a mixture thereof comprising at least 10 mol %, based on the entire amount of fatty acid or fatty acid derivative, of fatty acid having 12 carbon atoms or less or derivative of fatty acid having 12 carbon atoms or less, are mixed in a molar ratio of from 1:0.8 to 1:3.5, wherein the molar ratio is of the elementary metal or metal compound to the total amount of carboxylic groups in the at least one fatty acid, at least one fatty acid derivative or a mixture thereof, and reacted for a period P1 of from 5 min to 24 h at a temperature T1 which is above 270° C. and below 300° C. in the absence of added solvent, and
b) thereafter the temperature is raised to a temperature T2 which ranges from 300° C. to 400° C., and additional fatty acid, fatty acid derivative or a mixture thereof comprising at least 10 mol %, based on the entire amount of fatty acid or fatty acid derivative, of fatty acid having 12 carbon atoms or less or derivative of such fatty acid, is added over a period of time P2 of from 5 min to 24 h in the absence of added solvent until the molar ratio of the elementary metal or metal compound to the total amount of carboxylic groups in the at least one fatty acid, at least one fatty acid derivative or a mixture thereof is in the range of from 1:6 to 1:99.

US Pat. No. 11,110,162

RECOMBINANT ZIKA VACCINES

THEMIS BIOSCIENCE GMBH, ...


1. An infectious replicative virus particle comprising a measles virus vector backbone and a Zika virus E-protein, wherein the infectious replicative virus particle comprises in its genome at least two nucleic acid sequences, wherein (i) the first nucleic acid sequence encodes at least one E-protein of a Zika virus; and (ii) the second nucleic acid sequence encodes the measles virus vector backbone; wherein:(a) the first nucleic acid sequence is operably linked to the second nucleic acid sequence;
(b) the first nucleic acid sequence comprises, in sequential order:(1) a nucleic acid sequence encoding a capsid cleavage site, the capsid cleavage site comprising the residues arginine-arginine immediately preceding the nucleic acid sequence of (2) below;
(2) a nucleic acid sequence encoding at least one pre-membrane protein signal sequence;
(3) a nucleic acid sequence encoding a pre-membrane protein of a flavivirus;
(4) a nucleic acid sequence encoding an E-protein signal sequence; and
(5) a nucleic acid sequence encoding the at least one E-protein of a Zika virus, the nucleic acid sequence encoding at least one E-protein of a Zika virus having at least 75% sequence identity to the E-protein portion encoded by any one of SEQ ID NOs: 1 to 13 and 67 to 87, wherein(5a) the nucleic acid sequence encoding the at least one E-protein of a Zika virus does not comprise a sequence encoding a stem-anchor region; or
(5b) the nucleic acid sequence encoding the at least one E-protein of a Zika virus encodes a mutation at amino acid position 107 in comparison to the sequence of any one of SEQ ID NOs:40 to 52 and 130 to 150, and does not comprise a sequence encoding a stem-anchor region; or
(5c) the nucleic acid sequence encoding the at least one E-protein of a Zika virus encodes a mutation at position 107 in comparison to the sequence of any one of SEQ ID NOs:40 to 52 or 130 to 150, and comprises a sequence encoding a stem-anchor region of an E-protein of a Zika virus, or a heterologous stem-anchor region; and


(c) the infectious replicative virus particle does not comprise a nucleic acid sequence encoding a C-protein or a non-structural protein of a flavivirus.

US Pat. No. 11,110,163

HEAT STABLE VACCINES

Inventprise, LLC, Redmon...


1. An immunogenic composition comprising:an attenuated strain of a rotavirus at a titer of about 105.9 FFU/mL or higher;
arginine and sucrose at a ratio of from about 1:1.1-2.5;
less than or equal to about 1.2% moisture;
an approximate uniform particle size of about 5 ?m or less;
a buffering agent; and
medium-chain triglyceride (MCT).

US Pat. No. 11,111,448

DECAHYDRONAPHTHALENE AS AN ENDOTHERMIC FUEL FOR HYPERSONIC VEHICLES

Reaction Systems Inc., G...


1. A fuel composition which comprises 50% or more by volume of a mixture of the cis and trans isomers of decahydronaphthalene, wherein the molar ratio of cis to trans isomers ranges from 3.5 to 1.0 and which optionally comprises 0-3% by volume of tetrahydronaphthalene, 0-3% by volume of naphthalene, 0-10% by volume of methyl alcohol, ethyl alcohol, n-propyl alcohol, or a mixture thereof, and 0-25% by volume of methylcyclohexane.
US Pat. No. 11,110,164

LYSOSOMAL TARGETING OF ANTIGENS EMPLOYING NUCLEIC ACIDS ENCODING LYSOSOMAL MEMBRANE POLYPEPTIDE/ANTIGEN CHIMERAS

The Johns Hopkins Univers...


1. A DNA vaccine comprising a chimeric vector encoding a fusion protein which comprises a Gag polypeptide inserted between a trafficking domain and a transmembrane domain of a lysosomal membrane polypeptide, wherein the trafficking domain is the luminal domain of a lysosomal membrane polypeptide and directs both membrane and non-membrane proteins to an endosomal/lysosomal compartment in a cell or to a lysosome-related organelle.
US Pat. No. 11,111,193

TREATMENT OF A MIXED METAL OXIDE CATALYST CONTAINING MOLYBDENUM, VANADIUM, NIOBIUM AND OPTIONALLY TELLURIUM

SHELL OIL COMPANY, Houst...


1. A process for treatment of a used mixed metal oxide catalyst, the process comprising:oxidative dehydrogenation of a feed comprising an alkane containing 2 to 6 carbon atoms and/or oxidation of a feed containing an alkene containing 2 to 6 carbon atoms comprising contacting the feed containing the alkane and/or alkene with a mixed metal oxide catalyst comprising molybdenum, vanadium, niobium, and optionally tellurium to produce a used mixed metal oxide catalyst; and
contacting a gas stream comprising methane with the used mixed metal oxide catalyst at a temperature from 200 to 500° C. and at a pressure, wherein said gas stream comprises no or substantially no alkane containing 2 to 6 carbon atoms, no or substantially no alkene containing 2 to 6 carbon atoms, and no or substantially no oxygen.

US Pat. No. 11,110,165

THERAPEUTIC VACCINE FOR THE TREATMENT OF PAPILLOMAVIRUS LESIONS

Ricardo Rosales Ledezma, ...


1. A method of treating a cancer in an individual, comprising:administering a therapeutically effective amount of a pharmaceutical composition comprising the attenuated Lederle-Chorioallantoic GAB-1 strain of vaccinia virus to the individual, wherein the cancer is caused by human papillomavirus.

US Pat. No. 11,111,450

BASE OIL AND LUBRICANT OIL COMPOSITION INCLUDING THE SAME

Patech Fine Chemicals Co....


1. A base oil, comprising an ester compound obtained by reacting a fatty acid component and a monohydric alcohol component,wherein said fatty acid component includes a C4-C28 fatty acid,
wherein said monohydric alcohol component includes at least one C4-C22 straight chain monohydric alcohol and at least one C4-C22 branched chain monohydric alcohol, a total of said C4-C22 straight chain monohydric alcohol and said C4-C22 branched chain monohydric alcohol being not less than 3,
wherein among the total of said C4-C22 straight chain monohydric alcohol and said C4-C22 branched chain monohydric alcohol, at least one monohydric alcohol has 4 to 11 carbon atoms, at least one monohydric alcohol has 12 to 15 carbon atoms, and at least one monohydric alcohol has 16 to 22 carbon atoms,
wherein said at least one monohydric alcohol having 4 to 11 carbon atoms is present in an amount that ranges from 0.1 wt % to 5.0 wt % based on 100 wt % of said monohydric alcohol component, and
wherein said at least one monohydric alcohol having 16 to 22 carbon atoms is present in an amount that ranges from 0.1 wt % to 5.0 wt % based on 100 wt % of said monohydric alcohol component.

US Pat. No. 11,110,166

POLYMERIC CARRIER CARGO COMPLEX FOR USE AS AN IMMUNOSTIMULATING AGENT OR AS AN ADJUVANT


1. A pharmaceutical composition comprising:(A) a polymeric carrier cargo complex, comprising:a) as a carrier a polymeric carrier formed by disulfide-crosslinked cationic components, and
b) as a cargo at least one first nucleic acid molecule,

and
(B) at least one second nucleic acid molecule, wherein the at least one second nucleic acid molecule is an mRNA molecule encoding a protein, wherein the mRNA comprises a 5?-UTR of a TOP gene.

US Pat. No. 11,110,167

VACCINE ADJUVANT COMPOSITION COMPRISING INULIN PARTICLES

VAXINE PTY LTD, Adelaide...


1. A immunogenic vaccine composition comprising:(a) manufactured particles of delta inulin;
(b) a synthetic substance comprising one or more, but no greater than ten distinct molecular species of pathogen-associated molecular pattern (PAMP); and
(c) an antigen.

US Pat. No. 11,110,168

NANOPARTICLES, CONTROLLED-RELEASE DOSAGE FORMS, AND METHODS FOR DELIVERING AN IMMUNOTHERAPEUTIC AGENT

NORTH CAROLINA STATE UNIV...


1. A controlled-release pharmaceutical dosage form comprising:a CpG oligodeoxynucleotide nano-cocoon, wherein the nano-cocoon comprises an immunotherapeutic agent and inflammation-responsive nanoparticles, wherein the nanoparticles encapsulate a restriction enzyme, wherein the inflammation-responsive nanoparticles comprise triglycerol monostearate (TGMS), and wherein the restriction enzyme is HhaI, and wherein the immunotherapeutic agent is selected from an anti-PD1 antibody, an anti-PDL1 antibody, an anti-CTLA4 antibody, or a combination thereof.

US Pat. No. 11,111,454

LUBRICANT FORMULATION COMPRISING FRICTION MODIFIER ADDITIVE

Croda International PLC, ...


1. A lubricant formulation comprising:(a) a base oil selected from API Group I to V oils and mixtures thereof; and
(b) a friction modifier additive present in a range of from 0.01 to 10 wt % on the basis of the total weight of the lubricant formulation
wherein the friction modifier additive has a hydroxyl value in the range from 10 to 300 mg KOH/g when measured according to ASTM D1957-86 and the friction modifier additive is the reaction product of reactants comprising:
i) a dimer fatty acid;
ii) a polyol selected from ethylene glycol, diethylene glycol, triethylene glycol, polyethylene glycol, propylene glycol, dipropylene glycol, tripropylene glycol polypropylene glycol, butylene glycol, propanediol, butanediol, glycerol and mixtures thereof; and one or both of:
iii) a C2 to C12 aliphatic dicarboxylic acid or diol; and
iv) a C1 to C10 aliphatic mono-carboxylic acid or mono-alcohol.

US Pat. No. 11,110,170

ALUMINUM COMPOUNDS FOR USE IN THERAPEUTICS AND VACCINES

Valneva Austria GmbH, Vi...


1. An aqueous pharmaceutical composition or vaccine, comprising a protein and an aluminum salt, and wherein said aqueous pharmaceutical composition comprises less than 3 ppb copper (Cu) based on the weight of the composition.
US Pat. No. 11,111,199

METHODS FOR PREPARING FORMALDEHYDE FROM CARBON DIOXIDE

The Trustees of Columbia ...


1. A method for preparing formaldehyde, comprising the steps of:(a) obtaining a bis(silyl)acetal; and
(b) generating formaldehyde by any one of the following:adding a fluoride compound to a solution of the bis(silyl)acetal in a solvent; or
(ii) reacting the bis(silyl)acetal with water in a solvent; or
(iii) reacting the bis(silyl)acetal with an acid in a solvent.


US Pat. No. 11,111,455

LUBRICATING OIL COMPOSITION FOR AUTOMATIC TRANSMISSIONS

SHELL OIL COMPANY, Houst...


1. A lubricating oil composition for automatic transmissions, the lubricating oil composition comprising:a low viscosity base oil at a concentration of 60% to 98% by mass,wherein the low viscosity base oil comprises one or more of a Group 2 base oil, a Group 3 base oil, and a Group 4 base oil, with each of the Group 2 base oil, the Group 3 base oil, and the Group 4 base oil being categories defined by the American Petroleum Institute,
wherein the low viscosity base oil has a kinematic viscosity of 2 mm2/s to 5 mm2/s at 100° C., and
wherein at least 45% by mass of the low viscosity base oil comprises at least one Fischer-Tropsch synthetic oil;

a high viscosity base oil at concentration of 1% to 20% by mass,wherein the high viscosity base oil comprises a metallocene/poly-?-olefin, and
wherein the high viscosity base oil has a kinematic viscosity of a 100 mm2/s to 600 mm2/s at 100° C.; and

a polymethacrylate at a concentration of 1% to 20% by mass, wherein the polymethacrylate has a molecular weight of 10,000 to 50,000 by weight-average,
wherein the lubricating oil has:a kinematic viscosity of 5 mm2/s to 7 mm2/s at 100° C.;
a viscosity index of at least 190;
a low temperature (?40° C.) Brookfield viscosity of not more than 5000 mPa·s;
a rate of reduction of not more than 3% as measured by a KRL shear stability test of a 100° C. kinematic viscosity; and
an evaporation loss of not more than 10% by mass as measured by the NOACK method for 200° C./hour.


US Pat. No. 11,110,171

PD-1 RELATED CANCER THERAPY

New York University, New...


1. A method of treating an individual afflicted with cancer comprising:in a sample of blood cells obtained from the individual determining a level of signaling lymphocyte activation molecule-associated protein (SAP) to be lower than a reference SAP level, wherein the reference SAP level is the level of SAP from an individual or individuals without cancer; and administering to the individual afflicted with cancer a therapy comprising PD-1 inhibition therapy, and further comprising administering to the individual a SHP2 inhibitor.

US Pat. No. 11,110,172

METHOD FOR TREATING MULTILOCULATED HYDROCEPHALUS BY ADMINISTERING AN ANTI-IL6 RECEPTOR ANTIBODY

IMAM ABDULRAHMAN BIN FAIS...


1. A method for treating or reducing the severity of septated multiloculated hydrocephalus comprisingadministering to a human subject, who is suffering from septated multiloculated hydrocephalus, an antibody that binds to an IL-6 receptor in an amount that reduces proliferation of fibroglial tissue, thereby treating or reducing the severity of septated multiloculated hydrocephalus; wherein said antibody is Tocilizumab.

US Pat. No. 11,110,430

TREATMENT METHOD OF RADIOACTIVE IODINE-CONTAINING FLUID

EBARA CORPORATION, Tokyo...


1. A treatment method of a radioactive iodine-containing fluid, comprising passing the radioactive iodine-containing fluid through an adsorbent for iodine consisting of a silver-containing binderless zeolite molded body having a silver content of 50 mass % or less, to adsorb the radioactive iodine on the adsorbent for iodine, wherein the binderless zeolite molded body constituting the adsorbent for iodine is either a binderless A-type zeolite molded body alone or a binderless X-type zeolite molded body alone, and wherein the binderless zeolite molded body includes a zeolite powder and zeolite fine particles wherein the zeolite powder has on a surface thereof the zeolite fine particles, and an average particle size of the zeolite powder is 2 ?m or more and 8 ?m or less wherein the average particle size of the zeolite powder is determined by measuring the size of randomly extracting 30 or more of independent smallest unit of particles having a particle size of 1.5 ?m or less identifiable in a scanning electron microscope image at a measurement magnification of 10,000 to 15,000, and an average particle of the zeolite fine particles is 0.2 ?m or more and 1.5 ?m or less wherein the average particle size of the zeolite fine particles is determined by measuring the size of randomly extracting 30 or more of independent particles identifiable in a scanning electron microscope image at a measurement magnification of 1,500 to 3,000.
US Pat. No. 11,111,201

REDUCTION OF CONTENT OF CARBOXYLIC ACIDS AND DERIVATIVES THEREOF IN OLEUM, DISULFURIC ACID OR CONCENTRATED SULFURIC ACID

Solvay SA, Brussels (BE)...


1. A process for the reduction of a content of carboxylic acids and derivatives thereof in oleum, disulfuric acid or sulfuric acid, the process comprising submitting a first fraction comprising oleum, disulfuric acid or sulfuric acid with a first content of carboxylic acid or at least one anhydride derivative thereof to a gas stripping operation in order to obtain a second fraction comprising oleum, disulfuric acid or sulfuric acid with a second content of carboxylic acid or at least one anhydride derivative thereof, wherein the second content of carboxylic acid or at least one anhydride derivative thereof in the second fraction comprising oleum, disulfuric acid or sulfuric acid is lower than the first content of carboxylic acid or at least one anhydride derivative thereof in the first fraction comprising oleum, disulfuric acid or sulfuric acid,wherein the carboxylic acid and/or carboxylic acid anhydride derivative of the first content is a halogenated carboxylic acid of formula (I) HalR2C—C(O)—OH, wherein Hal is selected from the group consisting of F, Cl and Br, and wherein R is independently selected from the group consisting of H, F, Cl, Br, alkyl, and aryl, or a halogenated carboxylic acid anhydride derivative thereof.

US Pat. No. 11,111,457

LUBRICATING OIL COMPOSITION

IDEMITSU KOSAN CO., LTD.,...


1. A method to lubricate a continuously variable transmission (CVT), comprising:applying a lubricating oil composition between a pulley and a belt or between a pulley and a chain of the CVT;
wherein the lubricating oil composition comprises:
a base oil;
(A) an alkaline earth metal-based detergent (A) having a base number of from 10 to 500 mgKOH/g as measured according to the perchloric acid method of JIS K-2501,

wherein the amount of the alkaline earth metal atom derived from the alkaline earth metal-based detergent (A) is from 10 to 1,500 ppm by mass;(B1) 0.01 to 0.5% by mass of a phosphite ester (B1) represented by the following formula (I):(R1O)aP(OH)3-a??(I)
wherein R1 represents a hydrocarbon group having 2 to 24 carbon atoms; a represents an integer of 1 to 3; and when a is 2 or 3, R1's may be the same as or different from each other,

(B2) 0.01 to 0.5% by mass of a phosphate ester amine salt (B2) which is an amine salt of an acidic phosphate ester represented by the following formula (II):(R2O)bP(?O)(OH)3-b??(II)

wherein R2 represents a hydrocarbon group having 2 to 24 carbon atoms; b represents an integer of 1 or 2; and when b is 2, R2's may be the same as or different from each other,

(B3) 0.01 to 0.8% by mass of an acidic phosphate ester (B3) represented by the following formula (III):(R3O)cP(?O)(OH)3-c??(III)
wherein R3 represents a hydrocarbon group having 2 to 24 carbon atoms; c represents an integer of 1 or 2; and when c is 2, R3's may be the same as or different from each other,
(C1) 0.01 to 0.8% by mass of an aliphatic monoamine (C1) represented by the following formula (IV):NR4R5R6??(IV)

wherein R4 represents an aliphatic hydrocarbon group having 10 to 24 carbon atoms; R5 and R6 each represent a hydrogen atom or an alkyl group having 1 to 4 carbon atoms; and R5 and R6 may be the same as or different from each other, and
(C2) 0.05 to 0.7% by mass of an aromatic monoamine (C2) represented by the following formula (V):NR7R8R9??(V)

wherein R7 represents an aromatic hydrocarbon group having 6 to 12 carbon atoms; R8 and R9 each represent a hydrogen atom or an alkyl group having 1 to 4 carbon atoms; and R8 and R9 may be the same as or different from each other; and further wherein
an intermetallic friction coefficient according to ASTM D2714 of the lubricating oil is 0.114 or more, wherein the test is run under the following conditions:

Surface pressure: 0.8 GPa
Oil temperature: 90° C.
Average slipping velocity: 0.500 m/s
Time: 30 minutes

Surface pressure: 0.8 GPa
Oil temperature: 90° C.
Average slipping velocity: 0.500 m/s

Steel-steel;
and
a ratio of intermetallic friction-coefficient/slipping-velocity according to ASTM D2714 of the lubricating oil is 1.03 or less wherein the test is run under the following conditions:

Surface pressure: 0.8 GPa
Oil temperature: 90° C.
Average slipping velocity: 0.500 m/s
Time: 30 minutes

Surface pressure: 0.8 GPa
Oil temperature: 90° C.
Average slipping velocity: 0.025 m/s and 0.500 m/s

Steel-steel
? Ratio=(Friction coefficient at 0.025 m/s)/(Friction coefficient at 0.500 m/s).


US Pat. No. 11,110,173

PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM

AXSOME THERAPEUTICS, INC,...


1. A method of relieving migraine pain, comprising: orally administering to a human being in need thereof, a combination of: 1) a complex of a meloxicam and a sulfobutylether-?-cyclodextrin, 2) a bicarbonate, and 3) a rizatriptan, wherein the combination is orally administered when the human being is suffering from moderate to severe migraine pain of an acute migraine, and wherein one hour after the combination is orally administered, the human being experiences a greater reduction in migraine pain than the human being would experience one hour after the same amount of the meloxicam is orally administered alone.
US Pat. No. 11,110,431

ALUMINA HAVING ACIDITY AND STRUCTURE WITH A POROSITY WHICH ARE OPTIMAL

AXENS, Rueil Malmaison (...


1. An alumina exhibiting a structure with a porosity such that the content of pores having a diameter of between 70 and 2000 ? is between 0.15 and 0.50 ml/g, and comprising at least one alkali metal (M), such that the content by weight of alkali metal, expressed as M2O, is between 400 and 1500 ppm, with respect to the total weight of the alumina, wherein the alumina exhibits a BET specific surface area of at least 150 m2/g and wherein the alumina contains at most 500 ppm by weight of silica, expressed as SiO2.
US Pat. No. 11,110,688

ANTI-BLUSH AND CHEMICAL RESISTANT POLYESTER FILM

TORAY PLASTICS (AMERICA),...


1. A polymer film comprising an anti-blushing composition in a blend comprising polyethylene terephthalate (PET) and polybutylene terephthalate (PBT), wherein PBT is polymerized in presence of tetra-n-butyl titanate, tetraisopropyl titanate or combinations thereof;wherein the blend has an intrinsic viscosity greater than 0.765 and contains at least 50 wt. % of PBT;
wherein a melting point of the PET is greater than 244.5° C. and lower than 254.4° C.;
wherein a degree of transesterification between the PET and the PBT is greater than 0.3 mol % and less than 6.47 mol %;
wherein the anti-blushing composition excludes:
triphenyl phosphite,
bis(acetodeca)pentaerythritol diphosphite,
bis(2,6-di-t-butyl-4-methylphenyl)pentaerythritol dibenzophosphite,
bis(2,6-di-t-butyl-4-methylphenyl)pentaerythritol diphosphite,
bis(2,4-dicumylphenyl)pentaerythritol diphosphite,
2-[[2,4,8,10-tetrakis(1,1-dimethylether)dibenzo[d,f][1,3,2]dioxaphosphepin-6-yl]oxy]-N,N-bis[2-[2,4,8,10-tetrakis(1,1-dimethylether)dibenzo[d,f][1,3,2]dioxaphosphepin-6-yl)oxy]ethyl]ethanolamine,
diphenyl isodecylphosphite,
benzyl ethylphosphonate,
trimethyl phosphate,
triethyl phosphate,
tributyl phosphate,
ethyl diethylphosphonoacetate,
tri-2-ethylhexyl phosphate,
tris(2-chloroethyl)phosphate, and
bis(acetodeca)pentaerythritol diphosphite; and
wherein the anti-blushing composition comprises dialkyl pentaerythritol di phosphonate, pentaerythritol phosphonate or combinations thereof;
wherein the anti-blushing composition is configured to prevent blushing in the polymer film laminated directly to a metal sheet and exposed to steam at a temperature of 251° F. for 90 minutes, wherein the anti-blushing composition is about 0.01 wt. % to about 1 wt. % in the blend.

US Pat. No. 11,109,661

SYSTEM, DEVICE AND METHOD OF FACIAL REMODELING

New You Lift, LLC, Grand...


1. A system of facial remodeling comprising:a facial mask having a nose to ear portion and a central portion forming a first lifting strap;
a behind ear section coupled to the first lifting strap;
an upper neck portion forming a second lifting strap coupled to the behind ear section, wherein the first lifting strap and the second lifting strap are coupled together by the behind ear section; and
a tissue remodeling composition, wherein the facial mask is configured to support a facial tissue treated with the tissue remodeling composition.

US Pat. No. 11,111,459

LAUNDRY DETERGENT COMPOSITIONS WITH STAIN REMOVAL


1. A laundry detergent composition comprising:a) detersive surfactant, wherein the detersive surfactant comprises a combination of anionic and nonionic surfactant;
b) an enzyme system comprising:i. a xanthan endoglucanase, wherein said xanthan endoglucanase comprises a polypeptide with at least about 60% sequence identity to SEQ ID NO: 1;
ii. a xanthan lyase, wherein said xanthan lyase comprises a polypeptide with at least about 60% sequence identity to SEQ ID NO: 2, and
iii. a mannanase, wherein said selected from the group consisting of:a) mannanase having mannanase activity and a polypeptide having at least about 85% sequence identity to residues 27-331 of SEQ ID NO: 3, SEQ ID NO: 3 corresponds to the full-length amino acid sequence of the Man7 mannanase endogenous to Bacillus hemicellulosilyticus including a signal sequence;
b) mannanase has mannanase activity and a polypeptide having at least about 60% identity to SEQ ID NO: 4, the mannanase has mannanase activity and a polypeptide having at least 80% identity to SEQ ID NO: 4, wherein SEQ ID NO: 4 corresponds to the full-length amino acid sequence of the Man4 mannanase endogenous to Paenibacillus sp;
c) and mixtures thereof.



US Pat. No. 11,110,690

TIE LAYER COMPOSITIONS AND MULTILAYER FILMS INCORPORATING THE SAME

Dow Global Technologies, ...


1. A tie layer composition comprisingfunctionalized polyethylene, styrene block copolymer, base polyethylene, and antioxidant co-stabilizers,
wherein the antioxidant co-stabilizers comprise at least one oxygen scavenger comprising a phosphite, at least two peroxy free radical scavengers comprising sterically hindered phenolics, and at least one alkyl free radical scavenger comprising an acrylate, thereby demonstrating improved adhesion and viscosity control, and
wherein the tie layer composition comprises from 3000 to 10,000 ppm of the antioxidant co-stabilizers including 1000 to 4300 ppm of the alkyl free radical scavenger.

US Pat. No. 11,111,204

METHOD FOR PRODUCTION OF METHYL METHACRYLATE BY OXIDATIVE ESTERIFICATION USING A HETEROGENEOUS CATALYST

Dow Global Technologies L...


1. A method for preparing methyl methacrylate from methacrolein and methanol; said method comprising contacting a mixture comprising methacrolein, methanol and oxygen with a heterogeneous catalyst comprising a support and a noble metal, wherein said support comprises silicon, and wherein said catalyst comprises from 0.1 to 40 mol % titanium and from 0.1 to 10 mol % of at least one noble metal selected from the group consisting of gold, platinum, iridium, osmium, silver, palladium, rhodium, and ruthenium, wherein mole percentages are based on total moles of silicon atoms and metal atoms, wherein at least 90 wt % of the noble metal is in the outer 60% of catalyst volume.
US Pat. No. 11,111,460

METHOD FOR PREPARING STABLE COMPOSITION WITH PERFUME

RHODIA OPERATIONS, Paris...


1. A method for preparing a homogenous liquid composition comprising mixing a mixture of:a quaternary ammonium compound,
a cationic polysaccharide, wherein the cationic polysaccharide is present at from 0.2 to 10 wt. % of the composition, and
optionally a nonionic polysaccharide,
with a mixture of a fragrance material or perfume and a nonionic surfactant,

wherein the quaternary ammonium compound has the general formula (III):[N+((CH2)n-T-R8)m(R9)4-m]yX???(III)

wherein:
R8 group is independently selected from C1-C30 alkyl or alkenyl group;
R9 group is independently selected from C1-C4 alkyl or hydroxylalkyl group;
T is —C(?O)—O— or —O—C(?O)—;
n is an integer from 0 to 5;
m is selected from 1, 2 and 3;
X is an anion, for example a chloride, bromide, nitrate or methosulphate ion;
y is the valence of X.
US Pat. No. 11,110,176

COMPOSITION AND METHOD FOR THE PROTECTION OF PROTEINS, CELL COMPONENTS AND CELLS DURING TEMPERATURE STRESS

The Board of Trustees of ...


1. A composition, comprising:an antifreeze protein (AFP) selected from the group consisting of natural or engineered SEQ ID NO: 1 (DAFP-1), SEQ ID NO: 2 (DAFP-2), SEQ ID NO: 3 (DAFP-4) and SEQ ID NO: 4 (DAFP 6); and
a non-antifreeze protein selected from the group consisting of enzymes, hormones, antibodies, growth factors, therapeutic proteins, nutrient proteins and food proteins in need of protection against heat stress;
wherein the antifreeze protein and the non-antifreeze protein are present in a mass ratio of from 1:1 to about 1:1000.

US Pat. No. 11,110,434

RUTHENIUM-BASED CATALYST FOR HYDROGEN PRODUCTION FROM AMMONIA DECOMPOSITION, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF


1. A ruthenium-based catalyst for hydrogen production from ammonia decomposition, comprising an active component, a promoter and a carrier, wherein the active component is ruthenium, the promoter is cesium and/or potassium, and the carrier comprises a composite carrier of a metal oxide and an activated carbon.
US Pat. No. 11,111,205

PROCESS FOR PREPARING ALKANEDIOL AND DIALKYL CARBONATE

SHELL OIL COMPANY, Houst...


1. A process for the preparation of an alkanediol and a dialkyl carbonate comprising reacting an alkylene carbonate and an alkanol in the presence of a catalyst, wherein the catalyst is aluminum phosphate.
US Pat. No. 11,110,436

PHOSPHORUS COMPOUND-CONTAINING EXHAUST GAS PURIFYING CATALYST

UMICORE SHOKUBAI JAPAN CO...


1. A phosphorus compound-containing exhaust gas purifying catalyst, comprising:a refractory three-dimensional structure extending from a gas inflow side end surface to a gas outflow side end surface, the refractory three-dimensional structure having cell walls that define and form multiple gas flow paths, the gas flow paths running from the gas inflow side end surface to the gas outflow side end surface;
a lower catalyst layer that contains Pd and is formed continuously from the gas inflow side end surface on the cell walls;
a gas inflow side upper catalyst layer that contains Rh and is located on an uppermost layer on the cell walls, the gas inflow side upper catalyst layer being formed continuously from the gas inflow side end surface; and
a gas outflow side upper catalyst layer that contains Rh and is located on an uppermost layer on the cell walls, the gas outflow side upper catalyst layer being formed continuously from the gas outflow side end surface, wherein
the gas inflow side upper catalyst layer and the gas outflow side upper catalyst layer are disposed so as to be separated from one another along the gas flow path direction, and
the lower catalyst layer has a length along the gas flow path direction of 15 mm or more, and a length ratio is 18% or more and less than 100% of the total length of the gas flow paths.

US Pat. No. 11,110,693

LAMINATE AND COPOLYMER

DAIKIN INDUSTRIES, LTD., ...


1. A laminate comprising a rubber layer (A) and a fluororesin layer (B),the fluororesin layer (B) comprising a copolymer containing a chlorotrifluoroethylene unit, a tetrafluoroethylene unit, and a perfluoroalkyl vinyl ether unit,
the copolymer containing 96.0 to 97.4 mol % of the chlorotrifluoroethylene unit and the tetrafluoroethylene unit relative to all the monomer units constituting the copolymer and 2.6 to 4.0 mol % of the perfluoroalkyl vinyl ether unit relative to all the monomer units constituting the copolymer,
wherein a ratio of the chlorotrifluoroethylene unit to and the tetrafluoroethylene unit is 15-25 to 85-75, and
wherein the perfluoroalkyl vinyl ether is represented by the following formula:
CF2=CF—O—Rf
wherein Rf is a C1-C5 perfluoroalkyl group.

US Pat. No. 11,111,207

ONE POT, ONE STEP PROCESS FOR THE HALOGENATION OF AROMATICS USING SOLID ACID CATALYSTS


1. An improved one pot, one step process for the halogenation of substituted aromatic compound selected from hydroxy aromatic compound, aromatic aldehyde compound, halo substituted aromatics, amide substituted aromatic compound and amino aromatic compound, said process consists of:addition of halogenating agent selected from chlorine, bromine or iodine and solid acid catalyst to the mixture of substituted aromatic compound in solvent selected from ethylene dichloride, methanol, hexane, toluene, ethanol, higher alcohols, dimethylsulfoxide, dioxane, dimethylformamide, acetone, diethyl ether, butanol and benzylalcohol followed by stirring the reaction mixture at temperature in the range of 25 to 85° C. and at atmospheric pressure of 14 psig for the period in the range of 2 to 6 hrs to afford corresponding halogenated compound wherein said solid acid catalyst is selected from MoO3/TiO2, MoO3/SiO2, WO3/TiO2, WO3/SiO2, and Mo Si/Al (7.5);
wherein no mixed halogenated products are produced;
wherein said catalyst is recyclable.

US Pat. No. 11,111,463

SOLID CLEANSING COMPOSITIONS WITH TAURINE AND METHODS THEREOF

Colgate-Palmolive Company...


1. A solid cleansing composition, comprising:a soap; and
an ionic liquid comprising taurine and a Brønsted base selected from urea, arginine, lysine, acetamide, and guanidine.

US Pat. No. 11,113,527

AUGMENTED CODE SOLUTION

Smartglyph Limited, West...


1. A system comprising:a scanning device; and
a physical scannable element; and
a processor contained in the scanning device, the processor being configured to:interrogate a database to identify a non-physical two dimensional code that is associated with the physical scannable element subsequent to the physical scannable element being optically captured by the scanning device;
to decode the non-physical two-dimensional code and translate the non-physical two-dimensional code into a vector that identifies an active data package stored on a server;
send the vector to the server via a suitable network; and
process the active data package after having been pushed to the scanning device by the server.


US Pat. No. 11,110,179

COMBINATION OF CD33 ANTIBODY DRUG CONJUGATES WITH CHEMOTHERAPEUTIC AGENTS

Seagen Inc., Bothell, WA...


1. A method of treating CD33 expressing acute myeloid leukemia (AML) in a subject in need of such treatment, the method comprising:1) administering an anthracycline antibiotic, and a CD33 antibody drug conjugate (ADC) in an induction period of seven days, wherein the CD33-ADC comprises a humanized 2H12 antibody and a PBD cytotoxic agent, and wherein 10 ?g/kg or 20 ?g/kg of the CD33-ADC is administered on day one of the induction period and 10 ?g/kg of the CD33-ADC is administered on day four of the induction period;
wherein the anthracycline antibiotic: 1) is cytarabine and is administered on induction days 1-7; or 2) is daunorubicin and is administered on induction days 1-3; and
2) after the induction period, administering the CD33-ADC and cytarabine in up to four consolidation cycles each comprising seven days, wherein the CD33-ADC is administered on day 1 of each consolidations cycle at 10 ?g/kg or 20 ?g/kg, and wherein cytarabine is administered on days 1, 3, and 5 of each consolidation cycles at 3 mg/m2/day.

US Pat. No. 11,110,694

PACKAGING MATERIAL

SOREMARTEC S.A., Findel ...


1. Packaging material comprising:a) a core layer comprising a polymer matrix of polymeric material including at least one active substance having antimicrobial and/or antifungal activity dispersed in the polymer matrix,
b) a coating applied to a side of said core layer obtained from a lacquer or a polymeric paint including fillers of a phyllosilicate or hydrotalcite,
c) a coating for the release of an active antimicrobial and/or antifungal agent comprising encapsulated ethanol and a polymeric component selected from chitosan grafted with polyethylene glycol or cyclodextrin, a mixture of chitosan and polyethylene glycol and a polymer or mixture of polymers for printable paint applied to other side of the core layer.

US Pat. No. 11,111,464

METHOD OF MANUFACTURING AN AUTOMATIC DISHWASHING DETERGENT PRODUCT

RECKITT BENCKISER FINISH ...


1. An automatic dishwashing detergent product provided as a discrete dosage unit comprising a continuous, non-aqueous gel phase, the gel phase comprising 10 wt % to 50 wt. % of non-ionic surfactant and at least 20 wt % polymeric builder, wherein:the polymeric builder is in a dissolved state in the non-aqueous gel phase,
the non-ionic surfactant is one or more optionally end-capped alcohol alkoxylates,
the polymeric builder is made by the free radical polymerization of acrylic acid monomer and optionally one or more further ?,?-ethylenically unsaturated acids, wherein no more than 0.1 wt % of the total amount of the monomers are crosslinking monomers,
the free radical polymerization reaction occurs in a non-aqueous liquid reaction mixture comprising the non-ionic surfactant and 10 wt. % to 60 wt. % of at least one non-water solvent comprising a water-soluble organic solvent, without an intermediate step of drying the non-aqueous liquid to form a solid comprising the polymeric builder; and
the polymeric builder has a weight average molecular weight in the range of 1000-70000 g/mol.

US Pat. No. 11,110,438

METHODS FOR PREPARATION AND USE OF LIQUID SYNTHESIS CATALYSTS


1. A method of using a liquid synthesis catalyst, comprising:impregnating a silica oxide support with cobalt;
drying the impregnated silica oxide support with an inert gas at a temperature of about 90° C. to about 130° C.;
after drying with the inert gas, calcinating the impregnated silica oxide support in the presence of oxygen to produce a liquid synthesis catalyst;
positioning the liquid synthesis catalyst in a reactor;
bedding and packing the liquid synthesis catalyst in the reactor;
reducing the liquid synthesis catalyst with H2 gas;
cooling the reactor to about 110° C. to about 160° C. while purging with H2 gas and increasing the reactor pressure to a set pressure point;
activating the liquid synthesis catalyst by introducing a gas stream into the reactor, wherein the gas stream comprises H2 gas and CO from a CO source at a molar ratio of 2:1 H2 to CO; and
collecting the reaction products in a reaction vessel.

US Pat. No. 11,111,209

PROCESS FOR RECOVERING ACETONITRILE FROM ACRYLONITRILE WASTE STREAMS

Ascend Performance Materi...


21. A process for recovering acetonitrile, comprising the steps of:distilling a feedstock stream comprising methanol and acetonitrile present in an amount equal to or less than 10 wt % in a first distillation column to yield a crude acetonitrile stream,
treating the crude acetonitrile stream to remove hydrogen cyanide and produce an intermediate acetonitrile stream comprising less than 1 wt. % hydrogen cyanide, and
purifying the intermediate acetonitrile stream in a pressure swing distillation system to produce a recycle stream and an acetontrile product stream comprising at least 90 wt. % acetonitrile,
wherein the first distillation column operates at a pressure greater than 0 psig.

US Pat. No. 11,110,439

DELAFOSSITE-TYPE OXIDE FOR EXHAUST GAS PURIFICATION CATALYST, AND EXHAUST GAS PURIFICATION CATALYST USING SAME


1. A delafossite-type oxide for an exhaust gas purification catalyst, represented by a general formula ABO2,wherein Cu and Ag are comprised in the A site of the general formula, only Mn is comprised in the B site of the general formula, or Mn and one or more elements selected from the group consisting of Al, Cr, and Ga are comprised in the B site of the general formula, and Ag is comprised at a ratio of 0.001 at. % or more and less than 20 at. % in the A site of the general formula.

US Pat. No. 11,111,466

DEACTIVATION WIPE KIT

Veltek Associates, Inc., ...


1. A hazardous drug deactivation wipe kit, comprising:a first pouch having a one-way filling valve coupled to an end thereof, the first pouch containing a first wipe saturated in hypochlorite solution, wherein the first pouch is filled with hypochlorite solution following irradiation sterilization; and
a second pouch containing a second wipe saturated in a solution of thiosulfate, potassium permanganate, or alkaline potassium permanganate.

US Pat. No. 11,110,182

MULTIFUNCTIONAL RNA NANOPARTICLES AND METHODS FOR TREATING CANCER AND THERAPEUTIC RESISTANT CANCER

University of Cincinnati,...


1. A pRNA nanoparticle functionalized for targeted delivery of Mediator Subunit 1 (MED1) silencing RNA (siRNA) to human cancer cells via human epidermal growth factor receptor 2 (HER2) receptors, the nanoparticle comprising: a three-way junction (3-WJ) pRNA, a HER2-targeting RNA aptamer, and two different MED 1 siRNAs, wherein each of the HER-2 targeting RNA aptamer and the MED1 siRNAs is annealed to a separate extending arm of the 3-WJ pRNA, wherein the pRNA nanoparticle is selected from the group consisting of:pRNA-HER2mini apt-MED1-siRNA (SEQ ID NO: 13),
pRNA-HER2A1 apt-MED1-siRNA (SEQ ID NO: 14),
pRNA-HER2B3 apt-MED1-siRNA (SEQ ID NO: 15),
pRNA-HER2C3 apt-MED1-siRNA (SEQ ID NO: 16),
pRNA-HER2D3 apt-MED1-siRNA (SEQ ID NO: 17), and
pRNA-HER2E1 apt-MED1-siRNA (SEQ ID NO: 18).

US Pat. No. 11,110,183

METHOD OF DELIVERING GENES AND DRUGS TO A POSTERIOR SEGMENT OF AN EYE

University of South Flori...


1. A drug delivery system for delivering a drug to a posterior segment of an eye of a patient comprising:a multifunctional dendrimer-based nanoparticle (MDN) comprisingat least one modified polyamidoamine (PAMAM) dendrimer nanoparticle modified by using molecular extrusion to remove large particles and aggregates to obtain a size of about 10 nm;
at least one short hairpin RNA (shRNA)-encoding DNA molecule complexed to an outer surface of the at least one modified PAMAM dendrimer nanoparticle;
at least one natural cyclodextrin encapsulating pioglitazone on the outer surface of the at least one modified PAMAM dendrimer nanoparticle; and
a targeting agent targeting a CD44 receptor conjugated to the outer surface of the at least one modified PAMAM dendrimer nanoparticle wherein the targeting agent is selected from the group consisting of hyaluronic acid, cholera toxin B domain, arginylglycylaspartic acid (RGD) peptide, and Tat peptide; and

a pharmaceutically acceptable carrier.

US Pat. No. 11,110,441

CATALYST FOR PREPARING PYRIDINE BASE FROM SYNGAS, AND PREPARATION METHOD AND APPLICATION THEREOF

NANJING REDSUN BIOCHEMIST...


10. A catalyst for preparing a pyridine base from a syngas, comprising a carrier, an active component, a first auxiliary agent and a second auxiliary agent, wherein the carrier is a molecular sieve, the active component is Rh, the first auxiliary agent is one or more of Mn, Fe, Na and La, and the second auxiliary agent is one or more of Zn, Co, Cr, Bi and Cu, andwherein the active component Rh is 1-3% of the mass of the carrier, the first auxiliary agent is 1.5-5% of the mass of the carrier, and the second auxiliary agent is 5-11% of the mass of the carrier.

US Pat. No. 11,111,212

OXIDIZED DISULFIDE OIL SOLVENT COMPOSITIONS

Saudi Arabian Oil Company...


1. An oxidized disulfide oil (ODSO) mixture consisting of two or more primary oxidized disulfide oil (ODSO) compounds selected from the group consisting of(R—SO—S—R?), (R—SOO—S—R?), (R—SOO—SO—R?),
(R—SOO—SOO—R?), (R—SO—SO—R?), (R—SO—SOO—OH),
(R—SOO—SOO—OH), (R—SO—SO—OH), and (R—SOO—SO—OH), and mixtures thereof, and
at least one of a secondary oxidized disulfide oil (ODSO) compound selected from the group consisting of
(R—SOO—SO—R?),
(R—SOO—SOO—R?), (R—SO—SO—OH),
(R—SOO—SOO—OH), (R—SO—SO—OH), and (R—SOO—SO—OH), and mixtures thereof,
where R and R? are alkyl groups each of which comprises from 1-10 carbon atoms,
and wherein the ODSO compounds in the mixture correspond to oxidized disulfide oils present in an effluent refinery hydrocarbon stream recovered following the catalytic oxidation of mercaptans present in the hydrocarbon stream.

US Pat. No. 11,110,442

PROCESS FOR PREPARING A MOLDING COMPRISING ZINC AND A TITANIUM-CONTAINING ZEOLITE

BASF SE


1. A molding comprising zinc and a titanium-containing zeolitic material having framework type MWW, obtained by a process comprising:(i) providing a molding comprising a titanium-containing zeolitic material having framework type MWW;
(ii) preparing an aqueous suspension comprising a zinc source and the molding comprising a titanium-containing zeolitic material having framework type MWW prepared in (i);
(iii) heating the aqueous suspension prepared in (ii) under autogenous pressure to a temperature of the liquid phase of the aqueous suspension of from 100 to 200° C., thereby obtaining an aqueous suspension comprising a molding comprising zinc and a titanium-containing zeolitic material having framework type MWW; and
(iv) separating the molding comprising zinc and a titanium-containing zeolitic material having framework type MWW from the liquid phase of the suspension obtained in (iii);
wherein in (ii), the zinc source comprises a zinc compound which is soluble in water at a temperature and pressure of the liquid aqueous phase according to (iii).

US Pat. No. 11,110,185

COMBINATION FORMULATION

GE HEALTHCARE AS, Oslo (...


1. A pharmaceutical composition comprising:(i) a first active pharmaceutical ingredient (API) having greater than 10% hepatocellular uptake and biliary excretion, wherein the first API is gadoexetate; and,
(ii) a second API that is a metal chelate comprising a chelant or a derivative thereof and a paramagnetic metal ion, said second API having renal excretion and a lower level of hepatocellular uptake and biliary excretion than the first API;
(iii) a biocompatible carrier comprising excess free chelant in a form suitable for mammalian administration;
wherein the ratio of said first API to said second API is from 1:10 to 4:1.

US Pat. No. 11,110,446

CATALYTIC ARTICLES

BASF Corporation, Florha...


1. A method of treating an exhaust stream of an internal combustion engine comprising contacting the exhaust stream with a catalytic article, the catalytic article comprising:a substrate having a catalytic coating thereon, the catalytic coating comprising:a catalytic layer having a thickness, an inner surface proximate to the substrate, and an outer surface distal to the substrate,
wherein the catalytic layer comprises a noble metal component on support particles, wherein the concentration of the noble metal component towards the outer surface is greater than the concentration towards the inner surface, and wherein the catalytic layer comprises support particles having a bimodal particle size distribution comprising micron-scaled particles and nano-scaled particles.


US Pat. No. 11,111,473

METHOD AND SYSTEM FOR PRODUCING PRODUCTS BY FERMENTATION

VITO NV (VLAAMSE INSTELLI...


1. A method for producing solvents by fermentation, said method comprising the steps of:performing a first fermentation step by fermenting a feedstock in the presence of microorganisms forming a first product stream;
performing a pervaporation step on the first product stream forming a permeate;
performing a first condensation step by partially condensing the permeate forming a first condensate and a residue stream, wherein the first condensation step is performed at a first pressure being below atmospheric pressure;
performing a second condensation step by condensing the residue stream at a second pressure higher than the first pressure forming a second condensate;
distilling the second condensate to produce a stream enriched in a first range of solvents and a liquid stream depleted in the first range of solvents; and
decanting the first condensate together with the liquid stream forming a phase enriched in a second range of solvents and an aqueous phase.

US Pat. No. 11,110,447

THREE-ZONE TWO-LAYER TWC CATALYST IN GASOLINE WASTE GAS APPLICATIONS

Johnson Matthey (Shanghai...


1. A catalyst article for treating exhaust gas comprising:a substrate comprising an inlet end, an outlet end with an axial length L;
an inlet catalyst layer beginning at the inlet end and extending for less than the axial length L, wherein the inlet catalyst layer comprises an inlet palladium component;
an outlet catalyst layer beginning at the outlet end and extending for less than the axial length L, wherein the outlet catalyst layer comprises an outlet rhodium component;
wherein the outlet catalyst layer overlaps with the inlet catalyst layer;
wherein the inlet catalyst layer is essentially free of PGM metals other than the inlet palladium component; and
wherein the outlet catalyst layer is essentially free of PGM metals other than the outlet rhodium component.

US Pat. No. 11,111,474

BACTERIAL STRAIN PRODUCING 2,3-BUTANEDIOL AND OTHER METABOLITES


1. A Lactococcus lactis strain 43103 deposited at the Spanish Type Culture Collection under accession number CECT 9139, wherein said strain has an increased ability to produce acetoin and 2,3-butanediol and a decreased ability to produce lactic add when cultured under aerobic conditions.
US Pat. No. 11,111,475

NEURAL CELL EXTRACELLULAR VESICLES

UNIVERSITY OF GEORGIA RES...


1. A method of treating a human subject who has suffered a stroke, comprising administering to the subject an effective amount of a pharmaceutical composition comprising isolated extracellular vesicles (EVs) derived from non-transformed human neural progenitor cells, wherein the EVs are administered intravenously or intranasally.
US Pat. No. 11,111,476

METHOD FOR MANUFACTURING CILIARY MARGINAL ZONE-LIKE STRUCTURE

Sumitomo Chemical Company...


1. A method for producing a retinal pigment epithelium tissue comprising the steps:(a) preparing a cell aggregate from a pluripotent stem cell,
(b) culturing the cell aggregate to form a retinal tissue comprising 20% or more and 100% or less of cells positive for Chx10,
(c) culturing the retinal tissue of step (b) in a serum-free medium comprising a substance that enhances signal transduction mediated by Wnt and a substance inhibiting the FGF signal pathway, thereby obtaining a retinal tissue having a decreased proportion of Chx10 positive cells that is about 3% or less of the tissue and comprising MITF positive cells.

US Pat. No. 11,111,477

LIVE CELL CONSTRUCTS FOR PRODUCTION OF CULTURED MILK PRODUCT AND METHODS USING THE SAME

BIOMILQ, Inc., Durham, N...


1. A method of producing an isolated milk product from cultured mammary cells, the method comprising:(a) culturing a live cell construct in a bioreactor under conditions which produce the milk product,said live cell construct comprising:(i) a three-dimensional scaffold having an exterior surface, an interior surface defining an interior cavity, and a plurality of pores extending from the interior surface to the exterior surface;
(ii) a matrix material disposed on the exterior surface of the three-dimensional scaffold;
(iii) a culture medium disposed within the interior cavity and in fluidic contact with the internal surface; and
(iv) a confluent monolayer of polarized mammary cells disposed on the matrix material, wherein the mammary cells are selected from the group consisting of: live primary mammary epithelial cells, live mammary myoepithelial cells, live immortalized mammary epithelial cells, and live immortalized mammary myoepithelial cells, and wherein the polarized mammary cells comprise an apical surface from which the cultured milk product is secreted and a basal surface;

said bioreactor comprising an apical compartment that is in fluidic contact with the apical surface of the mammary cells, is substantially isolated from the interior cavity of the live cell construct, and is substantially free of cell culture medium; and

(b) isolating the cultured milk product secreted into the apical compartment from the apical surface of the mammary cells.

US Pat. No. 11,111,478

METHODS OF PRODUCING T MEMORY STEM CELL POPULATIONS

The United States of Amer...


1. A method of producing an isolated T memory stem cell population, the method comprising(a) isolating lymphocytes from a mammal; and
(b) sorting the lymphocytes using flow cytometry into a population comprising a phenotype comprising(i) CD95+ and/or CXCR3+; and
(ii) CD45RA+, CCR7+, and CD28+, to produce an isolated T memory stem cell population.


US Pat. No. 11,111,223

CRYSTALLINE FORMS OF OZANIMOD AND OZANIMOD HYDROCHLORIDE, AND PROCESSES FOR PREPARATION THEREOF

RECEPTOS LLC, New York, ...


1. A crystalline Form CS1 of ozanimod, wherein the X-ray powder diffraction pattern shows characteristic peaks at 2theta values of 12.1°±0.2°, 10.4°±0.2° and 4.2°±0.2° using CuK? radiation.
US Pat. No. 11,111,479

METHODS AND KITS FOR GUIDED STEM CELL DIFFERENTIATION


1. A method to modulate the relative osteogenic gene expression of a mesenchymal stem cell in the presence of osteocyte differentiation induction media by culturing the mesenchymal stem cell on a ball having a diameter and choosing a diameter between 500 ?m and 6 mm, excluding 3 mm, comprising: culturing the mesenchymal stem cell on a ball, comprising the chosen diameter between about 500 ?m and about 6 mm excluding 3 mm, wherein the level of the relative osteogenic gene expression of the mesenchymal stem cell decreases as the diameter of the substrate ball increases from about 500 ?m to about 3 mm, the level of the relative osteogenic gene expression of the mesenchymal stem cell increases as the diameter of the ball increases from about 3 mm to about 6 mm and the level of the relative osteogenic gene expression of the mesenchymal stem cell on a ball of a diameter about 3 mm is comparable to that of the mesenchymal stem cell on a flat plate.
US Pat. No. 11,110,195

ESCULENTIN 1A DERIVATIVES AND USES THEREOF

UNIVERSITY OF HOUSTON SYS...


1. A method for stimulating wound healing, comprising the step of contacting a wound with an antimicrobial component comprising an antibacterial peptide with a sequence at least 80% identical to the sequence of SEQ ID NO: 2 or a diastereomer thereof with a sequence at least 80% identical to the sequence of SEQ ID NO: 3.
US Pat. No. 11,111,480

CULTURE MEDIA FOR MULTIPOTENT STEM CELLS

HOPE BIOSCTENCES, LLC, S...


1. A growth medium for culturing mesenchymal stem cells comprising:a) a serum from about 1 percent to about 10 percent by volume;
b) a fibroblast growth factor from about 1 g/mL to about 10 ng/mL; and
c) either:i) an L-cysteine from about 0.5 mM to about 5 mM; or
ii) a glutathione from about 0.5 mM to about 5 mM;

d) an epidermal growth factor from about 1 ng/ml to about 10 ng/ml;
e) hydrocortisone from about 10 ng/mL to about 100 ng/mL;
f) calcium chloride from about 0.01 mM to about 0.1 mM;
g) insulin from about 0.5 mg/mL to about 5 mg/mL;
h) pituitary extract from about 10 ?g/mL to about 100 ?g/mL;
i) selenium from about 0.1 ?g/mL to about 1 ?g/mL;
j) stromal-derived factor from about 1 ng/mL to about 10 ng/mL;
k) sodium pyruvate from about 2 mg/mL to about 20 mg/mL;
l) transferrin from about 0.1 mg/mL to about 1 mg/mL; and
m) serum free medium balanced to 100 percent volume; and
wherein, a cultured mesenchymal stem cell is morphologically identical to a mesenchymal stem cell of a previous generation.

US Pat. No. 11,110,196

ARTICLES COMPRISING MALODOR REDUCTION COMPOSITIONS


1. An absorbent article comprising a topsheet, a backsheet, an absorbent core disposed between the topsheet and the backsheet, and a hot melt adhesive comprising a homogeneous linear ethylene/C3-C20 ?-olefin interpolymer, wherein a portion of the hot melt adhesive is disposed within the absorbent core, wherein the hot melt adhesive comprises a malodor reduction composition comprising a perfume mixture, wherein the hot melt adhesive comprises from about 0.020% to about 0.75%, by weight of the hot melt adhesive, of the malodor reduction composition, wherein the perfume mixture comprises at least two perfume materials selected from the group consisting of terpinyl acetate, methyl iso-eugenol, phenyl acetaldehyde dimethyl acetal, and patchone, and wherein the perfume mixture comprises from about 5% to about 30%, by weight of the perfume mixture, of the terpinyl acetate and the methyl iso-eugenol.
US Pat. No. 11,111,481

ATTENUATED VIRUS MUTATED AT SITES OF EVOLUTIONARILY CONSERVED RNA STRUCTURE

RAMOT AT TEL-AVIV UNIVERS...


1. An attenuated form of a virulent virus comprising an RNA encoding a viral protein or a nucleic acid sequence transcribable to said RNA, comprising at least one nucleotide in a region of evolutionarily conserved local RNA folding energy synonymously substituted to another nucleotide,wherein said region of evolutionarily conserved local RNA folding energy comprises folding energy below a predetermined threshold and said substitution increases said folding energy, or
said region of evolutionarily conserved RNA folding energy comprises folding energy above a predetermined threshold and said substitution decreases said folding energy, wherein said predetermined threshold is derived from the average local folding energy of a randomized sequence of the virulent virus, wherein said randomized sequence encodes an amino acid sequence which is identical to the amino acid sequence of said virulent virus;
and wherein said viral protein of said attenuated virus comprises an amino acid sequence which is identical to the amino acid sequence of said viral protein of the virulent virus and said at least one substitution decreases replicative fitness of said attenuated form of a virus as compared to said virulent virus.

US Pat. No. 11,111,482

GENETICALLY MODIFIED LACTATE-CONSUMING YEASTS AND FERMENTATION PROCESSES USING SUCH GENETICALLY MODIFIED YEASTS

CARGILL, INCORPORATED, W...


1. A genetically modified yeast comprising:a heterologous gene encoding monocarboxylic/monocarboxylate transporter polypeptide having monocarboxylic/monocarboxylate transporter activity, wherein the said monocarboxylic/monocarboxylate transporter polypeptide comprises an amino acid sequence having at least 90% sequence identity to any one of the following amino acid sequences: SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 76, or SEQ ID NO: 78, and
one or more heterologous genes encoding a lactate dehydrogenase polypeptide having lactate dehydrogenase activity, wherein the said lactate dehydrogenase polypeptide comprises an amino acid sequence having at least 90% sequence identity to any one of the following amino acid sequences: SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO: 70, SEQ ID NO: 72, or SEQ ID NO: 74, and
wherein the yeast is capable of consuming lactate and producing ethanol at a titer greater than 80 g/L when the yeast is present in a fermentation medium comprising lactate and hexose.

US Pat. No. 11,111,483

ENHANCED HAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS AND METHODS

B-MoGen Biotechnologies, ...


1. A fusion transposase comprising a TcBuster transposase amino acid sequence and a DNA sequence specific binding domain, wherein the TcBuster transposase amino acid sequence has at least 70% identity to full-length SEQ ID NO: 1 and an amino acid substitution of D189A, V377T, E469K, K573E, E578L, or any combination thereof, when numbered in accordance with SEQ ID NO: 1.
US Pat. No. 11,111,228

PROCESS FOR THE PREPARATION OF POMALIDOMIDE AND ITS PURIFICATION

Natco Pharma Limited, Hy...


1. A process for the preparation of pomalidomide form A comprising the steps of:a) reacting 3-nitrophthalic acid with acetic anhydride in presence of toluene to get 3-nitrophthalic anhydride,
b) reacting 3-nitrophthalic anhydride with 3-aminoglutarimide hydrochloride in presence of tri ethylamine and acetic acid solvent to get 2-(2, 6-dioxo-3-piperidyl)-4-nitro-isoindoline-1, 3-dione,
c) reducing the 2-(2, 6-dioxo-3-piperidyl)-4-nitro-isoindoline-1, 3-dione in the presence of Pd/C, dimethyl formamide solvent, and nitrogen, with hydrogen gas bubbled into the reaction mass, at 15° C. to 20° C. to get pomalidomide form A.

US Pat. No. 11,111,484

STREPTOCOCCUS BACTERIOPHAGE LYSINS FOR DETECTION AND TREATMENT OF GRAM POSITIVE BACTERIA

THE ROCKEFELLER UNIVERSIT...


1. A method for killing Staphylococcus and Streptococcus bacteria or for reducing a population of Staphylococcus and Streptococcus bacteria comprising the step of contacting the bacteria with a chimeric protein comprising the binding domain of the isolated lysin polypeptide comprising the amino acid sequence of SEQ ID NO:3 or variants thereof having at least 80% identity to the polypeptide of SEQ ID NO:3 and effective to kill Staphylococcus and Streptococcus bacteria, said binding domain operably linked or covalently attached to a heterologous protein or polypeptide, wherein the chimeric protein is biologically active to bind Staphylococcus and Streptococcus bacteria and kill the Staphylococcus and Streptococcus bacteria.
US Pat. No. 11,110,458

SYSTEM FOR DETECTION OF SPACED DROPLETS

Bio-Rad Laboratories, Inc...


1. A detection system for droplet-based assays, comprisinga droplet channel including a droplet inlet configured to receive droplets suspended in a carrier fluid;
a shell surrounding a portion of the droplet channel and having an input channel therein;
a porous cylinder disposed within the shell and having a central bore that forms a portion of the droplet channel, the porous cylinder having porous walls that provide fluid communication between a periphery of the porous cylinder and the central bore;
a source of dilution fluid connected to the input channel and disposed outside the shell;
a detection channel in fluid communication with, and disposed downstream from, the droplet channel;
a light source to generate light that irradiates the detection channel;
one or more pumps operable to (a) drive travel of droplets and carrier fluid through the central bore and the detection channel and (b) force flow of dilution fluid into the central bore via the porous walls; and
a detection region including a fluorescence detector and one or more optical elements, the one or more optical elements being configured to direct, to the fluorescence detector, fluorescence radiation emitted by droplets passing through the detection channel.

US Pat. No. 11,111,485

EXPRESSION SYSTEM FOR PSICOSE EPIMERASE AND PRODUCTION FOR PSICOSE USING THE SAME

SAMYANG CORPORATION, Seo...


1. A method of producing a psicose epimerase, comprising:culturing a recombinant Corynebacterium sp. cell transformed by a vector comprising a gene expression cassette, and
reacting a fructose-containing substrate with at least one selected from the group consisting of an psicose epimerase obtained from the culture of the recombinant Corynebacterium sp., a recombinant cell, a culture of the recombinant cell, a lysate of the recombinant cell and an extract of cell culture or the cell lysate, and
wherein the gene expression cassette, producing a psicose epimerase in Corynebacterium sp., and comprising:
a nucleotide sequence encoding the psicose epimerase; and
a regulating sequence being operably connected to the nucleotide sequence in the upstream regulating the expression of the nucleotide sequence in Corynebacterium sp., and comprising a promoter, a ribosome binding site (RBS) sequence and a first spacer sequence in the direction of 5? to 3?,
wherein the promoter includes the nucleotide sequence of SEQ ID NO: 1,
the ribosome binding site (RBS) sequence is a nucleotide sequence in a size of 7 to 20 bases including the nucleotide sequence of SEQ ID NO: 2, and
the first spacer sequence is selected from the group consisting of the nucleotide sequences of SEQ ID NO: 4 to SEQ ID NO: 6.

US Pat. No. 11,111,486

MUTANT GLUTATHIONE SYNTHETASE AND METHOD FOR PRODUCING GAMMA-GLUTAMYL-VALYL-GLYCINE

AJINOMOTO CO., INC., Tok...


1. A method for producing ?-Glu-Val-Gly and/or a salt thereof, the method comprising:reacting a mutant glutathione synthetase with ?-Glu-Val and Gly to generate ?-Glu-Val-Gly,
wherein the mutant glutathione synthetase has ?-glutamylvalylglycine synthetase activity and comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 2, where at least one amino acid residue in the mutant glutathione synthetase corresponding to the following amino acid residue (A) or (B) is mutated to a different amino acid:
(A) at least one amino acid residue selected from the group consisting of F22, M165, I274, T285, and P287 in SEQ ID NO: 2;
(B) a combination of at least one amino acid residue selected from the group consisting of V7, N13, I14, N15, K17, F95, N199, Y200, and P202 in SEQ ID NO:2 and the amino acid residue (A).

US Pat. No. 11,111,487

METHOD AND APPARATUS FOR ENCODING CELLULAR SPATIAL POSITION INFORMATION

SILICON VALLEY SCIENTIFIC...


1. A spatial preparation system comprising:a) a spatial sampler subsystem comprising:(1) a specimen holder comprising a plate having a flat surface, and, on the flat surface, a biological specimen comprising a tissue, and
(2) a multifunctional head comprising a transfer head comprising a plurality of extraction channels, wherein the extraction channels comprise openings covered with one or more transfer membranes, and wherein the extraction channels are in communication with a first liquid source under positive and/or negative pressure, and wherein the multifunctional head is mounted on a three axis stage to position the multifunctional head over the specimen holder at different spatial positions; and

b) a spatial encoder subsystem comprising:(1) a plurality of spatial encoder microchannels, each microchannel having an inlet, and each communicating with a common output microchannel at different first junctions;
(2) a reagent rail comprising a plurality of containers, each container comprising different marker molecules comprising different spatial information, wherein the reagent rail communicates with the common output microchannel;
(3) a microdroplet generator comprising a source of immiscible liquid in communication with the common output microchannel at a second junction downstream of the first junctions; and
(4) one or more pumps communicating with the spatial encoder microchannels, the common output microchannel, the reagent rail and the source of immiscible liquid; and

wherein:(1) the spatial sampler subsystem is configured:(i) to extract, by contact adhesion or by vacuum, a plurality of microsamples from each of a plurality of different original spatial positions on the biological specimen onto the one or more transfer membranes;
(ii) to move the multifunctional head using the stage to the inlets of the spatial encoder microchannels; and
(iii) to deliver through application of positive or negative pressure, each extracted microsample to an inlet of one of the spatial encoder microchannels in a pattern based on their original spatial position in the biological specimen; and

(2) the spatial encoder subsystem is configured:(i) to move each microsample from a spatial encoder microchannel to the common output microchannel through application of positive or negative pressure;
(ii) to move different marker molecules from containers in the reagent rail into the common output microchannel through application of positive or negative pressure; and
(iii) to generate microdrops in the common output channel, wherein the microdrops are spatially separated by the immiscible fluid, wherein a plurality of the microdrops comprise a microsample and a marker molecule.



US Pat. No. 11,110,203

DECELLULARIZATION OF PLANT CELL CULTURE MATERIALS FOR TISSUE ENGINEERING AND DRUG DELIVERY

Worcester Polytechnic Ins...


1. A method for decellularizing cells, the method comprising:contacting a plurality of plant cells with a composition comprising a nuclease comprising DNase, thereby decellularizing the plurality of plant cells, wherein the plurality of plant cells are cellulose producing plant cells.

US Pat. No. 11,111,488

METHODS FOR EXTRACTING BIOACTIVE SMALL RNAS FROM PLANTS AND MUSHROOMS

MIRNAGREEN S.R.L., Rover...


1. A method for isolating a fraction enriched of small RNA molecules from a fungal and/or plant sample, comprising:a?) incubating fungal and/or plant tissue or cells with an alkali metal bicarbonate solution at a temperature of 50-100° C., separating the liquid from the solid phase to obtain a liquid phase;
b) adding an alcohol solution to the liquid phase obtained in step a?) to obtain a solution;
c) loading the obtained solution to a solid support able to selectively bind small RNA molecules; and
d) eluting small RNA molecules from said solid support.

US Pat. No. 11,110,204

METHOD OF PRODUCING BIOABSORBABLE MEMBRANE

GC Corporation, Shizuoka...


1. A method of producing a bioabsorbable membrane including a first layer containing a first bioabsorbable polymer and a porous layer containing a second bioabsorbable polymer, the method comprising:forming a liquid membrane by spin-coating a coating liquid containing the first bioabsorbable polymer and a solvent; and
after forming the liquid membrane, forming the first layer and the porous layer by causing a porous membrane containing the second bioabsorbable polymer to contact the liquid membrane such that a part of the liquid membrane permeates into the porous membrane and by evaporating the solvent contained in the liquid membrane by drying.

US Pat. No. 11,111,489

MULTIPLEXED TESTING OF LYMPHOCYTES FOR ANTIGEN SPECIFICITY

Think Therapeutics, Inc.,...


1. A method for determining a lymphocyte cell receptor chain sequence, or a portion thereof, specific for at least two or more unique antigens, the method comprising:sorting a plurality of antigens into a plurality of reaction mixtures, wherein the sorting comprises adding the at least two unique antigens of the plurality of antigens to at least two unique subsets of the plurality of reaction mixtures such that the at least two unique antigens are not added to any two identical subsets of the plurality of reaction mixtures, and wherein the at least two unique subsets are configured to allow a detection of the at least two or more unique antigens that are specific to the lymphocyte cell receptor chain sequence;
contacting each reaction mixture of the plurality of reaction mixtures with a biological sample comprising a plurality of lymphocytes;
separating a target lymphocyte from a subset of the plurality of lymphocytes, wherein the target lymphocyte recognizes the at least two unique antigens of the plurality of antigens;
sequencing nucleic acids of the target lymphocyte to obtain the lymphocyte cell receptor chain sequence; and
detecting the at least two or more unique antigens that are specific to the lymphocyte cell receptor chain sequence.

US Pat. No. 11,109,949

LITHIUM SILICATE MATERIALS

Ivoclar Vivadent AG, Sch...


1. A lithium silicate dental glass-ceramic article comprising a machinable phase comprising lithium metasilicate crystalline phase that forms 30-40 vol % of the lithium silicate material, wherein the crystals in the crystalline phase are remote from each other.
US Pat. No. 11,110,205

FORMULA FOR SYNTHESIZING BONE REPLACEMENT MATERIAL, AND MANUFACTURING METHOD AND APPLICATION METHOD THEREOF

NOVUS LIFE SCIENCES LIMIT...


1. Bone material composite granules comprising a copolymer of hydroxyethyl methacrylate (HEMA) and methyl methacrylate (MMA); and calcium phosphate coating on the surface of the copolymer,wherein the mole ratio of HEMA to MMA is 1:4-1:12,
wherein the copolymer has an average diameter d1 in the range of 300 to 600 nm,
wherein the bone material composite granules have an average diameter d2 of 400 to 750 nm,
wherein the distribution ratio of the bone material composite granules in the size range of 400-750 nm is ?95%, and
wherein the setting time of the bone material composite granules ranges from 10-15 min.

US Pat. No. 11,111,234

SALT OF A QUINAZOLINE DERIVATIVE-LIKE TYROSINE KINASE INHIBITOR AND CRYSTAL FORM THEREOF

XUANZHU PHARMA CO., LTD.,...


1. Crystal form A of the maleate of the compound of Formula (1), (E)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-methoxylquinazolin-6-yl)-4-(2-azaspiro[3.3]heptan-2-yl)-2-butenamide,Formula (1)
wherein, the molar ratio of the compound of Formula (1) to maleic acid is 1:2,
wherein, the X-ray powder diffraction pattern of which has characteristic peaks at the 20 positions of 5.2±0.2°, 10.3±0.2°, 11.3±0.2°, 13.8±0.2°, 16.2±0.2°, and 19.9±0.2°, as determined by using Cu-K? radiation.

US Pat. No. 11,114,591

CORE-SHELL MATERIALS WITH RED-EMITTING PHOSPHORS

CURRENT LIGHTING SOLUTION...


1. A process for preparing a coated phosphor, the process comprising contacting a suspension of a phosphor material in particulate form in a HF solution, with a source of Mn4+, A+, and M, to form a coated phosphor having a shell comprising a first phosphor of formula I,Ax[MFy]:Mn4+??I

directly disposed on a core comprising a second phosphor; andconverting the coated phosphor to a color stable coated phosphor by contacting the already formed coated phosphor:with a fluorine-containing oxidizing agent in gaseous form at an elevated temperature ranging from about 350 degrees Celsius to about 700 degrees Celsius,
and with a compound of formula II, Ax[MFy] in an aqueous hydrofluoric acid, wherein the second phosphor is a material other than a compound of formula I or formula II; andAx[MFy]??II



wherein:contact with the compound of formula II in the aqueous hydrofluoric acid is one of: 1, before, or 2, both before and after, the coated phosphor is contacted with the fluorine-containing oxidizing agent in gaseous form at the elevated temperature ranging from about 350 degrees Celsius to about 700 degrees Celsius,
A is, independently at each occurrence, Li, Na, K, Rb, Cs, or a combination thereof;
M is, independently at each occurrence, Si, Ge, Sn, Ti, Zr, Al, Ga, In, Sc, Hf, Y, La, Nb, Ta, Bi, Gd, or a combination thereof;
x is the absolute value of the charge of the [MFy] ion; and
y is 5, 6 or 7.

US Pat. No. 11,110,206

SILK SERICIN-BASED HYDROGEL, METHODS AND USES THEREOF


1. A hydrogel comprising:at least 4% (w/v) of an enzymatically cross-linked silk sericin,
wherein the silk sericin is enzymatically cross-linked by an enzyme complex selected from the group consisting of: horseradish peroxidase and hydrogen peroxide, laccase, transglutaminase, and mixtures thereof;
wherein a cross-section of said hydrogel has pores with a diameter between 50-100 ?m, and;
wherein the hydrogel is suitable for medicinal applications, veterinary applications, cosmetic applications or as an in vitro model for cell culture studies.

US Pat. No. 11,111,491

METHODS FOR IMPROVING TRAITS IN PLANTS

PLANTARCBIO LTD., Raanan...


1. A plant comprising a transgeneencoding a polypeptide sequences having at least 90% identity to the polypeptide sequences set forth in SEQ ID NO: 213 and wherein the plant has one or more of the following characteristics: improved drought resistance, increased biomass, increased salinity tolerance.

US Pat. No. 11,111,492

GENOME ENGINEERING METHODS USING A CYTOSINE-SPECIFIC CAS9

Florida State University ...


1. A method for specifically manipulating nucleic acids in a cell comprising:contacting the cell with a cytosine-specific Cas9 endonuclease and a single guide RNA (sgRNA) targeting a protospacer sequence of the nucleic acids that is adjacent to a Protospacer Adjacent Motif (PAM) sequence of the nucleic acids,
wherein the cytosine-specific Cas9 endonuclease is a Type II-C Acidothermus cellulolyticus Cas9 (AceCas9).

US Pat. No. 11,111,493

GENE-REGULATING COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY

KSQ Therapeutics, Inc., ...


1. A primary human T cell comprising (a) a modified endogenous ZC3H12A gene and (b) an engineered antigen receptor that specifically binds to a tumor antigen,wherein ZC3H12A protein expression and/or function is reduced in the primary human T cell, relative to ZC3H12A protein expression and/or function in a primary human T cell expressing the endogenous ZC3H12A gene.

US Pat. No. 11,111,494

COMPOSITIONS FOR MODULATING ATAXIN 2 EXPRESSION

Ionis Pharmaceuticals, In...


1. An oligomeric compound comprising a modified oligonucleotide consisting of 14 to 30 linked nucleosides, wherein the nucleobase sequence of the modified oligonucleotide comprises a portion of at least 14 contiguous nucleobases, wherein the portion is complementary to:an equal length portion of nucleobases 1957-1988 of SEQ ID NO:1

wherein the modified oligonucleotide comprises at least one modification selected from a modified sugar moiety and a modified internucleoside linkage.
US Pat. No. 11,110,468

SEPARATION OF A MIXTURE USING MAGNETIC CARRIER PARTICLES

BASF SE, Ludwigshafen am...


1. A process for separating at least one first material from a mixture comprising this at least one first material, at least one second material and at least one third material, which comprises at least the following steps:(A) providing a mixture comprising at least one first material, at least one second material, at least one third material and at least one hydrocarbon in an amount of 0.5% by weight or more, based on the sum of mixture, in the presence or absence of at least one dispersion medium,
(B) optionally, adding at least one dispersion medium to the mixture obtained in step (A) in order to obtain a dispersion,
(C) treating the dispersion from step (A) or (B) with at least one hydrophobic magnetic particle, so that the at least one first material and the at least one magnetic particle agglomerate,
(D) separating the adduct from step (C) from the mixture by application of a magnetic field,
(E) optionally, dissociation of the adduct which has been separated off in step (D) in order to obtain the at least one first material and the at least one magnetic particle separately.

US Pat. No. 11,111,495

METHOD FOR GENERATING APTAMERS WITH IMPROVED OFF-RATES

Somalogic, Inc., Boulder...


1. A non-covalent complex of an aptamer and a target molecule, wherein the aptamer comprises at least one 5-position modified pyrimidine having a hydrophobic group attached via a linker to the 5-position of the pyrimidine, and wherein the aptamer has binding affinity for the target molecule.
US Pat. No. 11,111,496

METHODS AND MICROORGANISMS FOR MAKING 2,3-BUTANEDIOL AND DERIVATIVES THEREOF FROM C1 CARBONS

PRECIGEN, INC., Germanto...


1. A genetically modified microorganism capable of converting a Cl carbon to 2,3-BDO, wherein the microorganism is from the species Methylococcus capsulatus and comprises at least one heterologous gene encoding: i) an acetoin reductase; ii) an alpha-acetolactate decarboxylase; and/or iii) an acetolactate synthase.
US Pat. No. 11,111,497

TRANSGENIC PLANTS WITH ENGINEERED REDOX SENSITIVE MODULATION OF PHOTOSYNTHETIC ANTENNA COMPLEX PIGMENTS AND METHODS FOR MAKING THE SAME

NMC, INC., Los Alamos, N...


1. A DNA construct comprising a heterologous expression control sequence operatively linked to a polynucleotide sequence encoding a chlorophyll a oxidase, and wherein the expression control sequence interacts with a redox-sensitive modulator responsive to changes in ambient light intensity, wherein the redox-sensitive modulator is chosen from NAB1, GCD2, and GLD-1.
US Pat. No. 11,111,499

ISOLATED POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS OF USING SAME FOR INCREASING PLANT YIELD, BIOMASS, GROWTH RATE, VIGOR, OIL CONTENT, ABIOTIC STRESS TOLERANCE OF PLANTS AND NITROGEN USE EFFICIENCY

Evogene Ltd., Rehovot (I...


1. A method of increasing leaf number, growth rate of plot coverage and/or growth rate of rosette diameter of a plant, comprising:(a) over-expressing within the plant a polypeptide comprising an amino acid sequence at least 87% identical to SEQ ID NO: 638, wherein said over-expressing of said polypeptide is effected by transforming a cell of the plant with an exogenous polynucleotide comprising a nucleic acid sequence encoding said polypeptide, and
(b) selecting said plant over-expressing said polypeptide for an increased trait selected from the group consisting of: leaf number, growth rate of plot coverage and growth rate of rosette diameter as compared to a native plant of the same species under the same growth conditions,
thereby increasing the leaf number, growth rate of plot coverage and growth rate of rosette diameter of the plant.

US Pat. No. 11,111,500

MUTATED PROTOPORPHYRINOGEN IX OXIDASE (PPX) GENES

CIBUS US LLC, San Diego,...


1. A non-transgenic plant cell, resistant to one or more PPX-inhibiting herbicides, comprising a mutated protoporphyrinogen IX oxidase (PPX) gene, wherein said gene encodes a protein comprising a mutation at an amino acid position corresponding to position 426 of SEQ ID NO: 1, wherein the mutation is a Tyr to Phe substitution.
US Pat. No. 11,111,501

FUSARIUM HEAD BLIGHT DISEASE RESISTANCE

UNIVERSITY COLLEGE DUBLIN...


1. A method of genetically transforming a plant material comprising the steps of introducing into one or more cells of the plant material with a recombinant construct comprising the nucleotide sequence of SEQ ID NO: 1 or a functional variant of SEQ ID NO: 1 having at least 90% sequence identity with SEQ ID NO: 1, and expressing the nucleotide sequence or the functional variant thereof in the plant material; wherein the expression of the nucleotide sequence or the functional fragment thereof provides Fusarium Head Blight (FHB) disease resistance in the plant.
US Pat. No. 11,111,502

TOLCNDV RESISTANT MELON PLANTS

NUNHEMS B.V., Nunhem (NL...


1. A cultivated melon plant or plant cell comprising an introgression fragment on chromosome 11 and on chromosome 12 of a ToLCNDV resistant donor plant, wherein the introgression fragment on chromosome 11 comprises a sequence of the ToLCNDV resistant donor melon plant in-between SNP_01 at nucleotide 101 of SEQ ID NO: 1 and SNP_04 at nucleotide 101 of SEQ ID NO: 4, and wherein the introgression fragment on chromosome 12 comprises a sequence of the ToLCNDV resistant donor melon plant in-between SNP_05 at nucleotide 101 of SEQ ID NO: 5 and SNP_07 at nucleotide 101 of SEQ ID NO: 7, and wherein the introgression fragments on chromosome 11 and 12 are obtainable from seeds deposited under accession number NCIMB 42625, wherein the introgression fragment on chromosome 11 comprises a Thymine at nucleotide 101 of SEQ ID NO: 3 and the introgression fragment on chromosome 12 comprises a Guanine at nucleotide 101 of SEQ ID NO: 6.
US Pat. No. 11,111,503

METHOD FOR EXPRESSING PROTEIN GENE IN RESPONSE TO EXPRESSION OF MIRNA

Kyoto University, Kyoto ...


1. An artificial mRNA comprising:a sequence encoding a protein,
a miRNA target sequence linked to the 3?-terminal side of a Poly A sequence of at least 50 nucleotides, and
a translational repression sequence linked to the 3?-terminal side of the miRNA target sequence.

US Pat. No. 11,111,504

METHODS FOR SCARLESS INTRODUCTION OF TARGETED MODIFICATIONS INTO TARGETING VECTORS

Regeneron Pharmaceuticals...


1. A method for introducing a scarless targeted genetic modification in a preexisting targeting vector, comprising:(a) performing bacterial homologous recombination between the preexisting targeting vector and a modification cassette in a population of bacterial cells,wherein the modification cassette comprises the targeted genetic modification and comprises an insert nucleic acid flanked by a 5? homology arm corresponding to a 5? target sequence in the preexisting targeting vector and a 3? homology arm corresponding to a 3? target sequence in the preexisting targeting vector, wherein the insert nucleic acid comprises from 5? to 3?:
(i) a first repeat sequence;
(ii) a first target site for a first nuclease agent;
(iii) a selection cassette;
(iv) a second target site for a second nuclease agent; and
(v) a second repeat sequence identical to the first repeat sequence,
wherein the repeat sequence is at least about 20 nucleotides in length;

(b) selecting bacterial cells comprising a modified targeting vector comprising the selection cassette;
(c) cleaving the first target site in the modified targeting vector with the first nuclease agent and cleaving the second target site in the modified targeting vector with the second nuclease agent to remove the selection cassette and expose the first repeat sequence and the second repeat sequence in the modified targeting vector,
wherein step (c) occurs in vitro; and
(d) assembling the exposed first repeat sequence with the exposed second repeat sequence in an intramolecular in vitro assembly reaction to generate the targeting vector comprising the scarless targeted genetic modification,wherein neither the first target site for the first nuclease agent nor the second target site for the second nuclease agent are present and only a single copy of the repeat sequence is present in the targeting vector comprising the scarless targeted genetic modification.


US Pat. No. 11,111,505

METHODS AND COMPOSITIONS FOR TRANSDUCING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF

EXUMA BIOTECH, CORP., We...


1. A replication incompetent recombinant retroviral particle, comprising:A. one or more pseudotyping elements on the surface of the replication incompetent recombinant retroviral particle, wherein the one or more pseudotyping elements comprises a vesicular stomatitis virus (VSV-G) envelope protein, a feline endogenous virus (RD114) envelope protein, or a Paramyxoviridae envelope protein;
B. a polynucleotide comprising one or more transcriptional units, wherein each of the one or more transcriptional units is operatively linked to a promoter active in T cells, and wherein the one or more transcriptional units encodei. a first engineered signaling polypeptide comprising a lymphoproliferative element wherein the lymphoproliferative element comprises a cytokine receptor polypeptide comprising a signaling domain that is capable of activating a Stat pathway, and promoting proliferation and/or survival of T cells; and
ii. a second engineered signaling polypeptide comprising a chimeric antigen receptor comprising an antigen-specific targeting region, a transmembrane domain, and an intracellular activating domain; and

C. an activation element on the surface of the replication incompetent recombinant retroviral particle, wherein the activation element is fused to a heterologous membrane attachment sequence, wherein the activation element is a polypeptide capable of binding to CD3 on the surface of a resting T cell and activating the resting T cell and is not encoded by a polynucleotide in the recombinant retroviral particle and wherein the activation element comprises an anti-CD3 antibody.

US Pat. No. 11,111,250

POLYMORPHS OF RIBOCICLIB MONO SUCCINATE

SHILPA MEICARE LIMITED, ...


1. Crystalline Ribociclib mono succinate Form-SRS-I characterized by X-ray powder diffraction pattern comprising characteristic 2?° peaks at 9.0, 13.0, 15.2, 16.5, 17.3, 18.3, 20.0, 21.4, 21.6, 22.1, 23.6, 23.9 and 28.0±0.2 2?°.
US Pat. No. 11,111,506

COMPOSITIONS AND METHODS OF ENGINEERED CRISPR-CAS9 SYSTEMS USING SPLIT-NEXUS CAS9-ASSOCIATED POLYNUCLEOTIDES

Caribou Biosciences, Inc....


1. One or more expression cassettes comprising:one or more regulatory sequences operably linked to one or more polynucleotides encoding,a first Type II CRISPR-Cas9-associated split-nexus polynucleotide having a 5? end and a 3? end (sn1-casPN) comprising, in the 5? to 3? direction, a first stem element nucleotide sequence I and a nexus stem element nucleotide sequence I,
a second Type II CRISPR-Cas9-associated split-nexus polynucleotide having a 5? end and a 3? end (sn2-casPN) comprising, in the 5? to 3? direction, a nexus stem element nucleotide sequence II and a second stem element nucleotide sequence I, wherein the nexus stem element nucleotide sequence I of the sn1-casPN and the nexus stem element nucleotide sequence II of the sn2-casPN are capable of forming a nexus stem element by base-pair hydrogen bonding between the nexus stem element nucleotide sequence I and the nexus stem element nucleotide sequence II,
a third Type II CRISPR-Cas9-associated polynucleotide having a 5? end and a 3? end (sn3-casPN) comprising, in the 5? to 3? direction, a DNA target binding sequence and a first stem element nucleotide sequence II, wherein the first stem element nucleotide sequence I of the sn1-casPN and the first stem element nucleotide sequence II of the sn3-casPN are capable of forming a first stem element by base-pair hydrogen bonding between the first stem element nucleotide sequence I and the first stem element nucleotide sequence II,
a first adjunct polynucleotide having a 5? end and a 3? end comprising a second stem element nucleotide sequence II, wherein the second stem element nucleotide sequence I of the sn2-casPN and the second stem element nucleotide sequence II of the first adjunct polynucleotide are capable of forming a second stem element by base-pair hydrogen bonding between the second stem element nucleotide sequence I and the second stem element nucleotide sequence II,

wherein the one or more regulatory elements are capable of facilitating expression of a Type II CRISPR-Cas9-associated polynucleotide composition comprising the sn1-casPN, the sn2-casPN, the sn3-casPN, and the first adjunct polynucleotide.

US Pat. No. 11,111,507

METHOD FOR COUNTERSELECTION IN MICROORGANISMS

Zymergen Inc., Emeryvill...


1. A high-throughput (HTP) method for generating at least one scarless genomic edit in a Bacillus species, comprising:providing a plasmid or linear DNA construct comprising a sequence of interest, a positive selectable marker, and two copies of the ?-subunit of phenylalanyl-tRNA ligase (PheS) as counterselectable markers, wherein each of the counterselectable markers have been independently codon optimized for the Bacillus species and have a maximum continuous identity length of 500 base pairs when aligned with each other, and wherein each counterselectable marker is operably linked to at least one promoter;
transforming the Bacillus species with the DNA construct;
selecting for a Bacillus strain having integrated the DNA construct based on the positive selectable marker;
selecting for a Bacillus strain having undergone a homologous recombination event excising the backbone of the plasmid containing the counterselectable markers to produce a loop-out strain; and
screening the loop-out strain for the presence of the sequence of interest to produce a modified Bacillus strain having at least one scarless genomic edit.

US Pat. No. 11,111,508

MODIFIED CAS9 COMPOSITIONS AND METHODS OF USE

BRANDEIS UNIVERSITY, Wal...


1. A Cas9 fusion polypeptide having the sequence of SEQ ID NO:2.
US Pat. No. 11,111,509

BIO-ASSISTED PROCESS FOR CONVERSION OF MIXED VOLATILE FATTY ACIDS TO SELECTIVE DROP-IN FUELS

Indian Oil Corporation Li...


1. A bio-assisted process for production of drop-in fuels from CO2 and a volatile fatty acid rich source, said process comprising:(a) providing a first electrochemical system comprising at least one working electrode, at least one counter electrode, and a medium inoculated with selectively enriched electro-active bacteria selected from the group consisting of Geobacter anodireducens, Clostridium ljungdahlii, Acetobacterium woodii, Sporomusa acidovorans, Propionibacterium acidifaciens, Acetobacterium carbinolicum, Pseudomonas stutzeri MTCC 25027, Pseudomonas fragi MTCC 25025, Pseudomonas aeruginosa MTCC 5389, Psuedomonas alcaligenes, Schewanella putrefaciens, Clostridium aciditolerans, Enterobacter aerogenes MTCC 25016, Shewanella sp. MTCC 25020, and combinations thereof;
(b) providing feedstock to the first electrochemical system of step (a), wherein the feedstock comprises CO2 with the volatile fatty acid rich source;
(c) intensifying carboxylic acids in the feedstock of step (b) to obtain an effluent comprising intensified carboxylic acids;
(d) providing a second electrochemical system comprising at least one working electrode, at least one counter electrode, and a medium inoculated with selectively enriched electro-active bacteria selected from the group consisting of Sporomusa ovate, Clostridium acetobutylicum, Clostridium butyricum, Clostridium acidurici, Pseudomonas aeruginosa MTCC 5388, Pseudomonas putida MTCC 5387, Clostridium carboxidivorans, Clostridium beijerinckii, Schewanella oneidensis, Geobacter sdfurreducens, Clostridium cellutolyticum, Clostridium cellulosi, Clostridium cellulovorans, Alicaligens sp. MTCC 25022, Serratia sp. MTCC 25017, Lysinibacillus sp. MTCC 5666, and combinations thereof; and
(e) reducing the intensified carboxylic acids of step (c) in the second electrochemical system to obtain the drop-in fuels;wherein the working electrode of the first electrochemical system is composed of a material selected from the group consisting of graphite plate, carbon brush, carbon paper, graphite felt, activated carbon cloth, and combinations thereof;
wherein the counter electrode of the first electrochemical system is modified with a material selected from the group consisting of carbon nanotube (CNT), graphene, charcoal, activated carbon, stainless steel (SS) mesh, nickel oxide, zinc oxide, and iron oxide;
wherein the volatile fatty acid rich source comprises at least 0.5% formic acid, provided that if the formic acid is not already present in the feedstock the feedstock is supplemented with at least 0.5% formic acid;
wherein the working electrode of the second electrochemical system is composed of a material selected from the group consisting of graphite plate, graphite rod, carbon brush, carbon paper, carbon plate, graphite felt, activated carbon cloth, and combinations thereof; and
wherein the counter electrode of the second electrochemical system is modified with a material selected from the group consisting of CNT, Co9S8, graphene, FTO/NiO, Ni/Fe layered double hydroxide, Si/TiO2 nanowires, charcoal, activated carbon, nickel oxide, zinc oxide, and iron oxide; and
wherein the drop-in fuels are selected form the group consisting of methanol, ethanol, butanol, acetic acid, propanoic acid, butanoic acid, valeric acid, and caproic acid.


US Pat. No. 11,111,510

FERMENTATION PROCESS FOR THE PRODUCTION OF LIPIDS

LanzaTech New Zealand Lim...


1. A method for producing at least one lipid product from a gaseous substrate, the method comprising:i. receiving a gaseous substrate comprising CO2 and H2 in a first bioreactor containing a culture of at least one microorganism in a liquid nutrient medium, and fermenting the gaseous substrate under anaerobic conditions to produce acetate;
ii. passing at least a portion of the acetate to a second bioreactor containing a culture of at least one microalgae in a liquid nutrient medium, and fermenting the acetate under aerobic conditions to produce at least one lipid product, wherein the microalgae is selected from the group consisting of Thraustochytrium, Japonochytrium, Aplanochytrium, Elina, and Labyrinthula;
iii obtaining a fermentation broth from the second bioreactor; and
iv. passing at least a portion of the fermentation broth from the second bioreactor to a separator to produce a product stream comprising at least one lipid and biomass and an acetate depleted permeate stream;
v. passing the permeate stream to an oxygen removal unit to remove oxygen and then recycling at least a portion of the resulting oxygen depleted stream to the first bioreactor.

US Pat. No. 11,111,255

ZIRCONIUM-BASED METAL-ORGANIC FRAMEWORK MATERIAL UIO-66(ZR), RAPID ROOM-TEMPERATURE PREPARATION METHOD AND APPLICATION THEREOF

TONGJI UNIVERSITY, Shang...


1. A rapid room-temperature preparation method of a zirconium-based metal-organic framework material UiO-66(Zr), comprising the following steps:(1) mixing a zirconium source and an organic ligand uniformly to obtain a mixture, then placing the mixture in methanol to obtain a mixed solution and stirring the mixed solution at room temperature, centrifuging the mixed solution to obtain a centrifuged product and then discarding a supernatant of the centrifuged product to obtain a transparent gel-like intermediate product; and
(2) heating and drying the transparent gel-like intermediate product obtained in step (1) to obtain the zirconium-based metal-organic framework material UiO-66(Zr);
wherein the zirconium source is zirconium oxychloride octahydrate.

US Pat. No. 11,111,256

HIGH PURITY TRISILYLAMINE, METHODS OF MAKING, AND USE

Jiangsu Nata Opto-Electro...


8. A method of making a silylamine, the method comprising: combining ammonia and a compound comprising aminosilane functionality, wherein the compound comprising aminosilane functionality is an organic polymer comprising one or more groups according to formula (II)—N(R2)a(H)b(SiH3)2?a?b??(II)
where R2 is H, C1-20 hydrocarbyl, or —Si(R3)3, where R3 is C1-6 hydrocarbyl, subscript a and b independently are 0 or 1, and a+b<2, where the groups according to formula (II) are in pendant, terminal, or pendant and terminal positions on the organic polymer.

US Pat. No. 11,111,512

METHOD FOR PRODUCING 5-HYDROXYTRYPTOPHAN

BLRH BIOTECH CO., Baodin...


1. A method for producing 5-HTP, by Bacillus licheniformis JSC-69 deposited under accession number CGMCC 13533, said method comprising the following steps:Step a) culturing of Bacillus licheniformis said Bacillus licheniformis JSC-69;
Step b) adding tryptophan to said culture of step a) and transforming the tryptophan to 5-HTP by said Bacillus licheniformis JSC-69;
Step c) collecting the 5-HTP.

US Pat. No. 11,111,513

METHODS OF REMOVING ONE OR MORE COMPOUNDS FROM A LIGNOCELLULOSIC HYDROLYSATE VIA GAS STRIPPING, AND RELATED SYSTEMS

POET Research, Inc., Sio...


1. A method of removing at least a portion of furfural from a hydrolysate composition, wherein the method comprises:a) providing a whole broth hydrolysate composition, wherein the providing comprises:i) providing lignocellulosic biomass comprising hemicellulose, cellulose, and lignin;
ii) contacting the lignocellulosic biomass with an aqueous composition to hydrolyze at least a portion of the hemicellulose into one or more oligosaccharides and/or one or more pentoses, and form a first whole broth hydrolysate composition comprising at least pentose, cellulose, lignin, and furfural; and
iii) enzymatically hydrolyzing at least a portion of the cellulose in the first whole broth hydrolysate composition to form a second whole broth hydrolysate composition comprising at least pentose, hexose, lignin, and furfural, wherein the furfural is present in the second whole broth hydrolysate in a first concentration;

b) separating a first portion of the second whole broth hydrolysate composition and a second portion of the second whole broth hydrolysate composition from the second whole broth hydrolysate composition;
c) injecting a first volume of a gas into the first portion of the second whole broth hydrolysate composition to provide a treated, whole broth hydrolysate composition, wherein the treated, whole broth hydrolysate composition comprises furfural in a second concentration, wherein the second concentration is less than the first concentration;
d) recovering a second volume of the gas from the treated, whole broth hydrolysate composition, wherein the second volume of the gas comprises furfural;
e) adding a first cell mass of yeast to the treated, whole broth hydrolysate composition;
f) propagating the first cell mass of yeast in the treated, whole broth hydrolysate composition to form a second cell mass of yeast;
g) adding the treated, whole broth hydrolysate composition, including the second cell mass of yeast, to the second portion of the second whole broth hydrolysate composition; and
h) after “g”, fermenting the treated, whole broth hydrolysate composition, including the second cell mass of yeast, and the second portion of the second whole broth hydrolysate composition.

US Pat. No. 11,111,260

METHODS FOR FORMING 1,3,5,7-TETRAALKYL-6-(2,4-DIMETHOXYPHENYL)-2,4,8-TRIOXA-6-PHOSPHAADAMANTANE

Dow Global Technologies L...


1. A method for forming 1,3,5,7-tetraalkyl-6-(2,4-dimethoxyphenyl)-2,4,8-trioxa-6-phosphaadamantane, comprising:obtaining a solution comprising an ethereal solvent and an aluminum hydride;
adding dichloro(2,4-dimethoxyphenyl)phosphine to the solution to produce 2,4-dimethoxyphenylphosphine, wherein the solution has a temperature from greater than ?20° C. to 50° C. throughout the method; and
reacting the 2,4-dimethoxyphenylphosphine with an acidic mixture comprising diones to produce 1,3,5,7-tetraalkyl-6-(2,4-dimethoxyphenyl)-2,4,8-trioxa-6-phosphaadamantanes.

US Pat. No. 11,111,516

MALR-KNOCKOUT BACILLUS LICHENIFORMIS STRAIN, CONSTRUCTION METHOD AND USE


1. A method of making a malR-knockout Bacillus licheniformis, the method comprising the steps of:(1) using genomic DNA of Bacillus licheniformis DW2 as a template, obtaining an upstream homology arm of the malR gene and a downstream homology arm of the malR gene by polymerase chain reaction (PCR) amplification;
(2) connecting the upstream homology arm of the malR gene and the downstream homology arm of the malR gene by overlap extension PCR to obtain a target gene segment;
(3) performing double digests of the target gene segment by XbaI and BamHI restriction enzymes to obtain a digested gene segment;
(4) preparing plasmid T2(2)-ori, and performing double digests of the plasmid T2(2)-ori by XbaI and BamHI restriction enzymes to obtain a linear plasmid segment;
(5) ligating the digested gene segment obtained in step 3 and the linear plasmid segment obtained in step 4 by DNA ligase to obtain a knockout plasmid T2(2)-?malR;
(6) transforming the knockout plasmid T2(2)-?malR into Bacillus licheniformis DW2, and screening to obtain a positive transformant using kanacillin as a screening marker;
(7) after transferring and culturing the positive transformant for several times at 45° C., performing colony PCR to obtain positive single crossover binder strains that have single crossover between the upstream homology arm of the malR gene/the downstream homology arm of the malR gene and the genomic DNA of Bacillus licheniformis DW2;
(8) selecting the positive single crossover binder strain that has single crossover between the upstream homology arm of the malR gene and the genomic DNA of Bacillus licheniformis DW2, and also selecting the positive single crossover binder strain that has single crossover between the downstream homology arm of the malR gene and the genomic DNA of Bacillus licheniformis DW2; mixed culturing both in a 37° C. culturing medium absent of kanacillin, transferring and culturing for several times; and obtaining a malR-knockout Bacillus licheniformis DW2?malR by PCR screening;
wherein, Bacillus licheniformis DW2 is deposited in the China Center for Type Culture Collection (CCTCC) in Wuhan on Oct. 12, 2011 having a deposit number CCTCC NO: M2011344;
wherein the malR genomic DNA sequence of the Bacillus licheniformis DW2 comprises SEQ ID NO: 1.

US Pat. No. 11,111,261

IRON COMPLEX COMPOUNDS FOR THERAPEUTIC USE


1. A process for preparing an iron complex compound comprising the steps of(i) obtaining an iron preparation from iron pentacarbonyl, wherein the iron preparation comprises iron in a form selected from a water-soluble iron salt, an iron hydroxide, an iron oxide-hydroxide and a mixture of two or more thereof, whereinthe amount of arsenic in the iron preparation does not exceed 4.5 ?g per g of iron, and
the amount of lead in the iron preparation does not exceed 1.5 ?g per g of iron;

(ii) reacting the iron preparation with a ligand in the presence of water so as to form the iron complex compound,
(iii) recovering said iron complex compound, and
(iv) formulating said iron complex compound for parenteral administration.

US Pat. No. 11,111,518

MEDIUM FOR THE SPECIFIC DETECTION OF RESISTANT MICROORGANISMS


1. A method of detecting and distinguishing between any extended-spectrum ?-lactamase-producing E. coli bacteria (ESBL E. coli bacteria) and any extended-spectrum ?-lactamase-producing KESC bacteria (ESBL KESC bacteria) that are present on a culture medium, the method comprising:inoculating a culture medium with a biological sample, wherein the culture medium comprises:a first substrate for detecting beta-galactosidase activity;
a second substrate for detecting beta-glucuronidase activity;
a third substrate for detecting desaminase activity; and
a combination of antimicrobials throughout the entire culture medium, the combination comprising a cephalosporinase inhibitor and a third-generation cephalosporin; and

simultaneously detecting and distinguishing between any ESBL E. coli bacteria and ESBL KESC bacteria that are present on the culture medium.

US Pat. No. 11,111,519

SEQUENCING OF NUCLEIC ACIDS VIA BARCODING IN DISCRETE ENTITIES

The Regents of the Univer...


1. A method of introducing multiple copies of a first nucleic acid barcode to nucleic acids of a discrete entity, the method comprising:encapsulating a plurality of nucleic acid target molecules in a discrete entity;
flowing the discrete entity in a first channel to a junction;
flowing a continuous, unsegmented reagent flow comprising multiple copies of a first nucleic acid barcode and multiple copies of a second nucleic acid barcode in a second channel to the junction;
flowing a carrier fluid in a third channel to the junction, wherein the second channel comprising the continuous, unsegmented reagent flow is positioned between the first channel comprising the discrete entity and the third channel comprising the carrier fluid;
merging the discrete entity into the continuous, unsegmented reagent flow downstream of the junction; and
downstream of the junction, inducing the continuous, unsegmented reagent flow to break off one individual microdroplet comprising the plurality of nucleic acid target molecules of the discrete entity, multiple copies of the first nucleic acid barcode, and no copies of the second nucleic acid barcode, such that substantially all of the plurality of nucleic acid target molecules of the discrete entity are broken off into the one individual microdroplet.

US Pat. No. 11,111,264

MORPHIC FORMS OF 4-AMINO-7-(3,4-DIHYDROXY-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-2-METHYL-7H-PYRROLO[2,3-D]PYRIMIDINE-5-CARBOXAMIDE AND USES THEREOF

Chimerix, Inc., Durham, ...


1. Crystalline 4-amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide hemihydrate.
US Pat. No. 11,111,520

COMPOSITIONS AND METHODS FOR ENRICHING POPULATIONS OF NUCLEIC ACIDS

Karius, Inc., Redwood Ci...


1. A method of enriching microbial cell-free nucleic acids, the method comprising:(a) identifying nucleic acid length ranges at which a ratio of microbial cell-free nucleic acid to host cell-free nucleic acid is favored;
(b) providing a host sample wherein the sample is selected from the group consisting of blood, plasma, serum, saliva, cerebrospinal fluid, synovial fluid, and lavage wherein the host sample comprises host cell-free nucleic acids and the microbial cell-free nucleic acids; and
(c) enriching the microbial cell-free nucleic acids relative to the host cell-free nucleic acids by enriching for nucleic acid length ranges at which a ratio of microbial cell-free nucleic acid to host cell-free nucleic acid is favored.

US Pat. No. 11,111,521

COMPOSITIONS AND METHODS FOR ANALYTE DETECTION

President and Fellows of ...


1. A method for biological analysis, comprising:(a) providing a cell or tissue sample, wherein said cell or tissue sample comprises an analyte at a spatial location in said cell or tissue sample;
(b) binding a detection reagent to said analyte at said spatial location, wherein said detection reagent comprises (i) a probe that binds to said analyte and (ii) one or more pre-determined subsequences;
(c) performing a plurality of detection steps at said spatial location to obtain a time series of signal signatures corresponding to said analyte, wherein said plurality of detection steps comprises (i) detecting a first detectable label associated with said one or more pre-determined subsequences to obtain a first signal signature at said spatial location at a first time point of said time series; (ii) removing said first detectable label from said one or more pre-determined subsequences; and (iii) detecting a second detectable label associated with said one or more pre-determined subsequences to obtain a second signal signature at said spatial location at a second time point of said time series, wherein said second time point of said time series is subsequent to said first time point of said time series; and
(d) using said time series of signal signatures to identify said analyte at said spatial location in said cell or tissue sample.

US Pat. No. 11,111,522

METHOD FOR DETECTING TARGET NUCLEIC ACID SEQUENCES

XIAMEN UNIVERSITY, Xiame...


1. A method for detecting the presence of n target nucleic acid sequences in a sample, wherein, n is an integer of ?2, and, said method comprises the following steps:(1) for each target nucleic acid sequence to be detected, providing at least one upstream oligonucleotide sequence and at least one mediator probe; wherein, said upstream oligonucleotide sequence comprises a sequence complementary to said target nucleic acid sequence; and, said mediator probe comprises in 5? to 3? direction, a mediator sequence and a target specific sequence, said mediator sequence comprises a sequence not complementary to said target nucleic acid sequence, and, said target specific sequence comprises a sequence complementary to said target nucleic acid sequence; and, when hybridizing with said target nucleic acid sequence, said upstream oligonucleotide sequence is located upstream to said target specific sequence; and, the mediator sequences comprised in all the mediator probes are different from each other;
and, under a condition that allows nucleic acid hybridization, contacting the sample with the upstream oligonucleotide sequences and the mediator probes as provided;
(2) under a condition that allows cleavage of mediator probes, contacting the product of Step (1) with an enzyme having 5? nuclease activity;
(3) providing m detection probes, and under a condition that allows nucleic acid hybridization, contacting the product of Step (2) with said m detection probes, wherein,
m is an integer less than n and greater than 0, and
each detection probe independently comprises in 3? to 5? direction, one or more capture sequences complementary to one or more mediator sequences or parts thereof, and a templating sequence; and, said m detection probes comprise at least n capture sequences, which are complementary to the mediator sequences or parts thereof of the mediator probes provided in Step (1), respectively; and,
each detection probe is independently labeled with a reporter group and a quencher group, wherein, said reporter group can generate a signal, and, said quencher group can absorb or quench the signal generated by said reporter group; and, the signal, as generated by each detection probe when hybridizing with its complementary sequence, is different from the signal, as generated when not hybridizing with its complementary sequence; and,
(4) under a condition that allows extension reaction of a nucleic acid polymerase, contacting the product of Step (3) with a nucleic acid polymerase;
(5) subjecting the product of Step (4) to melting curve analysis; and according to the result of melting curve analysis, determining whether each target nucleic acid sequence is present in said sample;
optionally, said method further comprises the following steps: (6) according to the result of the melting curve analysis, determining the level of the target nucleic acid sequence corresponding to each melting peak.

US Pat. No. 11,111,268

USE OF QUATERNARY AND TERTIARY AMMONIUM CATIONS TO DENATURE PROTEINS

Agilent Technologies, Inc...


1. A method of denaturing a glycoprotein or glycopeptide of interest in vitro, said method comprising incubating said glycoprotein or glycopeptide in vitro with a solution comprising an effective amount of an ammonium cation sulfate or sulfonate detergent comprising (a) an aliphatic chain of 8-24 carbons, (b) a sulfate or sulfonate anion and (c) a tertiary or quaternary ammonium cation, wherein said aliphatic chain is covalently attached to said anion, for a time T to denature said glycoprotein or glycopeptide, thereby denaturing said glycoprotein or glycopeptide.
US Pat. No. 11,111,269

HYDROPHOBIC INTERACTION PROTEIN CHROMATOGRAPHY UNDER NO-SALT CONDITIONS

Biogen MA Inc., Cambridg...


1. A method of purifying an antibody, the method comprising:subjecting an antibody in solution to hydrophobic interaction chromatography in flow through mode using a matrix containing hydrophobic ligands with a mobile phase buffer, wherein the mobile phase buffer does not contain a kosmotropic salt and has a pH of about 5.0 to about 7.0.

US Pat. No. 11,111,525

METHODS, KITS AND COMPOSITIONS PERTAINING TO THE SUPPRESSION OF THE DETECTABLE PROBE BINDING TO RANDOMLY DISTRIBUTED REPEAT SEQUENCES GENOMIC NUCLEIC ACID

Applied Biosystems, LLC, ...


1. A method for comparing a sample of genomic nucleic acid with that of a control sample using a genomic nucleic acid reference array, said method comprising:a) providing a sample of genomic nucleic acid to be tested;
b) providing a control of genomic nucleic acid, wherein the control and the sample are differentially labeled;
c) providing a genomic nucleic acid reference array;
d) providing a mixture of two or more non-nucleotide probes wherein one probe of the mixture comprises a nucleobase sequence that is at least ninety percent homologous to a sequence selected from the group consisting of: SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO: 13, and another probe of the mixture comprises a nucleobase sequence selected from the group consisting of: TT(k)TTTTT(k)TTTLysOLysOTTT(k)TTTTT(k)TT and AA(k)AAAAA(k)AAALysOLysOAAA(k)AAAAA(k)AA, wherein (k) is D-lysine, Lys is L-lysine, and O is 8-amino-3,6-dioxaoctanoic acid;
e) treating the sample and control genomic nucleic acid, the array or both the sample and control genomic nucleic acid and the array with the mixture of non-nucleotide probes under suitable hybridization conditions;
f) contacting the array with the treated mixture of sample and control genomic nucleic acid under suitable hybridization conditions; and
g) comparing the intensities of the signals from the differential labels of the array to be caused by hybridization of the probes to genomic nucleic acid thereby determine one or more variations in copy numbers of sequences in the sample as compared with the relative copy numbers of substantially identical sequences in the control.

US Pat. No. 11,111,526

BUFFER COMPOSITION FOR HYBRIDIZATION AND HYBRIDIZATION METHOD

Toyo Kohan Co., Ltd., To...


1. A method of hybridizing a target nucleic acid comprising a detection target nucleotide with a nucleic acid probe comprising a nucleotide sequence complementary to a region comprising at least the detection target nucleotide in the target nucleic acid, whereinthe method comprises: mixing a solution comprising a nucleic acid mixture consisting of the target nucleic acid and a non-target nucleic acid comprising a non-detection target nucleotide corresponding to the detection target nucleotide, with a buffer composition for hybridization containing a blocking nucleic acid comprising a nucleotide sequence complementary to a region comprising at least the non-detection target nucleotide in the non-target nucleic acid, in a concentration 1 to 3 times higher than the concentration of both the target and non-target nucleic acids in the nucleic acid mixture; and then hybridizing the nucleic acid probe with the target nucleic acid,
wherein the solution comprising the nucleic acid mixture contains the target nucleic acid at a percentage of 0.5% to 10%, when the total percentage of the target nucleic acid and the non-target nucleic acid is set at 100%, and
wherein the nucleic acid mixture contains the target nucleic acid in a concentration of 0.66 nM to 3.3 nM.

US Pat. No. 11,111,271

THERAPEUTIC PEPTIDES

COHBAR, INC., Menlo Park...


or C-terminal acids or amides, or N-acetyl derivatives thereof; or

pharmaceutically acceptable salts thereof.
US Pat. No. 11,111,527

NANOPORE PLATFORM FOR DNA/RNA OLIGO DETECTION USING AN OSMIUM TAGGED COMPLEMENTARY PROBE


1. A method for detecting the presence of a nucleic acid target molecule in a biological sample, the method comprising the steps of:(a) contacting a test sample that comprises (i) a biological sample comprising a nucleic acid target molecule and (ii) an osmylated single-stranded oligonucleotide probe comprising at least one pyrimidine residue covalently bonded to a substituted or unsubstituted Osmium tetroxide (OsO4)-2,2?-bypyridine group (OsBp group), wherein the sequence of the probe is at least partially complementary to the sequence of the nucleic acid target molecule, to allow the formation of a hybridized probe/target complex,
wherein at least one osmylated pyrimidine residue is a thymidine residue (T);
(b) using a nanopore device to detect in the test sample the number of events wherein unhybridized osmylated-probe traverses the nanopore; and
(c)(i) comparing the number of events detected in the test sample to a number of corresponding probe sample events wherein unhybridized osmylated-probe traverses the nanopore in the absence of the nucleic acid target molecule, wherein a reduction in the number of events detected in the test sample relative to the number of probe sample events is indicative of the formation of the hybridized probe/target complex in step (a) and the presence of the nucleic acid target molecule in the test sample;
(c)(ii) comparing the number of events detected in the test sample to the noise of a corresponding baseline sample that does not contain any osmylated-probe, wherein an absence of an increase in the number of events detected in the test sample relative to the noise of the baseline sample is indicative of the formation of the hybridized probe/target complex in step (a) and the presence of the nucleic acid target molecule in the test sample; and/or
(c)(iii) comparing the number of events detected in the test sample to a number of corresponding control sample events wherein unhybridized osmylated-probe traverses the nanopore in the presence of a known amount of the nucleic acid target molecule, wherein a reduction in the number of events detected in the test sample relative to the number of control sample events is indicative of increased formation of the hybridized probe/target complex in step (a) and the presence of a higher amount of the nucleic acid target molecule in the test sample over the control sample or wherein an increase in the number of events detected in the test sample relative to the number of control sample events using the same amount of probe is indicative more unhybridized probe and thus of a lower amount of the nucleic acid target molecule in the test sample compared to the control sample.

US Pat. No. 11,111,272

?4?7 PEPTIDE MONOMER AND DIMER ANTAGONISTS

Protagonist Therapeutics,...


1. A method for treating Celiac disease in a subject, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a peptide dimer compound comprising two monomer subunits, wherein each monomer subunit comprises the amino acid sequence:Pen-(N-Me-Arg)-Ser-Asp-Thr-Leu-Pen-Phe(4-tBu)-(?-homo-Glu)-(D-Lys) (SEQ ID NO:153)

or a pharmaceutically acceptable salt thereof.
US Pat. No. 11,111,528

METHOD AND APPARATUS FOR ULTRASENSITIVE QUANTIFICATION OF MICRORNA USING AN ATOMIC FORCE MICROSCOPE AND A HYBRID BINDING DOMAIN

POSCO, Pohang-si (KR) PO...


1. An atomic force microscope comprising a cantilever, wherein said cantilever comprises a probing tip and a probe that is immobilized on said probing tip, wherein said probe comprises a hybrid binding domain (HBD) or a variant thereof, wherein said variant of HBD is elected from the group consisting of:an HBD linked to a glutathione S-transferase (GST);
an HDB linked to a histidine-tag; and
a biotinylated HBD,

and wherein said HBD is capable of binding to a minor groove of a DNA/RNA hybrid duplex.
US Pat. No. 11,111,786

MOISTURE TOLERANT ROCK DUST AND METHODS OF APPLICATION THEREOF

Imerys USA, Inc., Roswel...


1. A method of inerting coal dust, comprising:combining a surface-treated hydrophobic inorganic particulate material with water to form a mine rock dust composition;
applying the mine rock dust composition in the form of a non-foaming slurry;
wherein the surface of the inorganic particulate material is treated with a fatty acid, salt thereof, or ester thereof; and
wherein the surface treatment level of the inorganic particulate material ranges from 0.1 wt % to 5.0 wt % based on the weight of the inorganic particulate material.

US Pat. No. 11,111,274

NEUTRALISING ANTIBODY AGAINST DENGUE FOR USE IN A METHOD OF PREVENTION AND/OR TREATMENT OF ZIKA INFECTION

INSTITUT PASTEUR, Paris ...


1. A method for increasing an immune response against one or more flaviviruses in a subject, wherein the one or more flaviviruses is not a dengue virus, the method comprising administering a flavivirus Envelope Dimer Epitope (EDE) to the subject,wherein the EDE is a stabilized recombinant flavivirus-envelope glycoprotein E ectodomain (sE) dimer, wherein the dimer is:covalently stabilized with at least one disulphide inter-chain bond between the two sE monomers, and/or
non-covalently stabilized by substituting at least one amino acid residue in the amino acid sequence of at least one sE monomer with at least one bulky side chain amino acid, at the dimer interface or in domain I (DI)/domain III (DIII) linker of each monomer,
covalently stabilized with at least one sulfhydryl-reactive crosslinker between the two sE monomers, and/or
covalently stabilised by being formed as a single polypeptide chain, optionally with a linker region, optionally a Glycine Serine rich linker region, separating the sE sequences, and/or
covalently stabilized by linking the two sE monomers through modified sugars; and/or,
wherein the dimer is a homodimer or heterodimer of native and/or mutant envelope polypeptides, from any one or two of DENV-1, DENV-2, DENV-3, DENV-4, Zika or other flavivirus.


US Pat. No. 11,111,530

METHODS FOR HIGH LEVEL MULTIPLEXED POLYMERASE CHAIN REACTIONS AND HOMOGENEOUS MASS EXTENSION REACTIONS

Agena Biosciences, Inc., ...


1. A method for performing multiplexed amplification of target nucleic acid, comprising:(a) forming a mixture containing 7 or more pairs of primary and secondary primers and one or more target nucleic acids, wherein each primer pair amplifies a nucleic acid-target region of a target nucleic acid and a sequence tag is attached to one or both of the primary and secondary primers of one or more primer pairs; and
(b) amplifying a plurality of nucleic acid-target regions of (a) under amplification conditions, whereby at least 60% of the 7 or more nucleic acid-target regions attempted are amplified by the 7 or more amplification primer pairs to produce an amplified mixture of nucleic acid-target regions, wherein the amplification conditions comprise a multiplicity of thermocycles and amplification reactants comprising a polymerase, dNTPs and MgCl2, wherein the ratio of the concentration of MgCl2 to the concentration of each one of the dNTPs is less than or equal to 10:1 and only a single primer pair is used to amplify each particular nucleic acid target-region.

US Pat. No. 11,111,275

COMPOSITIONS AND METHODS FOR MAKING AND USING VIRUS-LIKE PARTICLES (VLPS)

The University of Massach...


1. A vaccine comprisinga) a recombinant Newcastle disease virus-like particle (ND VLP), said ND VLP comprises one or more recombinant chimeric mutation-stabilized pre-fusion F proteins that comprise a) SEQ ID NO:12, b) SEQ ID NO:10, or c) a combination of both SEQ ID NO:12 and SEQ ID NO:10, and
b) a physiologically acceptable carrier.

US Pat. No. 11,111,531

ISOTHERMAL METHODS FOR AMPLIFYING NUCLEIC ACID SAMPLES

TANGEN BIOSCIENCES, INC.,...


1. A two-stage multiplexed nucleic acid amplification and real-time detection method comprising a. providing a composition comprising a target nucleic acid template and a combination of site-specific primers that anneal to the target nucleic acid template near a region of interest to be amplified; b. performing a first isothermal reaction to amplify the region of interest, thereby forming a primary amplicon; c. dividing (b) into at least two secondary reactions, and including in at least one of the reactions one or more site-specific secondary primer that is complementary to a site-specific primer binding site that may be present within the primary amplicon and defines a site of interest within the region of interest; d. performing a second isothermal reaction (second-stage reaction) thereby accelerating the amplification of the region of interest only if the site-specific primer binding site is complementary to the site-specific primer; and e. detecting and comparing the amplification rates of the at least two secondary reactions, wherein an enhanced relative rate of amplification in the reaction with the secondary primer indicates the presence of the site of interest that is complementary to the secondary primer.
US Pat. No. 11,111,276

EPITOPE-SUBSTITUTED VACCINE FOR USE IN IMPROVING SAFETY AND IMMUNOGENICITY AGAINST DENGUE VIRUSES

ACADEMIA SINICA, Taipei ...


1. A method for neutralizing and protecting against one or more dengue virus serotypes infection, and/or for neutralizing a dengue virus, reducing, alleviating antibody dependent enhancement of dengue virus infection, and/or increasing survival rate in a subject in need thereof, comprising:administering to the subject in need thereof a therapeutically effective amount of a plasmid expressing a mutant dengue virus E protein comprising an amino acid sequence that is at least 80% identical to SEQ ID NO; 1, wherein the mutant dengue virus E protein has one or more amino acid residue substitutions at position corresponding to Asn8, Arg9, Val12, and/or Glu13 of SEQ ID NO: 1.

US Pat. No. 11,111,277

INFLUENZA VACCINES

InvVax, Inc., Pasadena, ...


1. A polypeptide comprising influenza virus epitopes, wherein the polypeptide comprises the sequences of SEQ ID NOs: 2, 3, 8, 11, 12, 17, 21, 22, 24, 32, 33, 34, 40, 41, 43, 49, 51, 52, 58, 59, 61, 62, 70, 73, 74, 75, 76, 77, 78, 82, 84, 85, 86, 92, 93, and 94.
US Pat. No. 11,111,533

GENERALIZED STOCHASTIC SUPER-RESOLUTION SEQUENCING

ILLUMINA CAMBRIDGE LIMITE...


1. A method for sequencing polynucleotides comprising:attaching a first DNA template molecule to a first attachment element of a plurality of attachment elements of a sample container and attaching a second DNA template molecule to a second attachment element of the plurality of attachment elements, wherein a distance between the first attachment element and the second attachment element is less than Abbe's limit;
providing a stochastic photo-switching chemistry to the sample container, the stochastic photo-switching chemistry comprising a set of nucleotides that have a 5? diphosphate quencher molecule and 3? phosphate block with a label moiety, a polymerase to incorporate a nucleotide of the set of nucleotides and cleave the 5? diphosphate quencher molecule, and an enzyme to cleave the 3? phosphate block with the label moiety;
imaging a series of on and off events for the first DNA template molecule in real-time as the on and off events are occurring, each on event occurring when the polymerase incorporates a nucleotide of the set of nucleotides and cleaves the 5? diphosphate quencher molecule and each off event occurring when the enzyme cleaves the 3? phosphate block with the label moiety;
imaging a series of on and off events for the second DNA template molecule in real-time as the on and off events are occurring, wherein the series of on and off events for the first DNA template molecule and the series of on and off events for the second DNA template molecule are stochastic and not synchronized; and
controlling a rate at which the on and off events occur;
wherein controlling the rate at which the on and off events occur comprises adjusting concentrations of nucleotides and enzymes used in the stochastic photo-switching chemistry so that a probability that an on event for a nucleotide base for the first DNA template molecule will occur at the same time as an on event for a nucleotide base for the second DNA template molecule is lower than a determined error rate in a sequencing application in which the method is applied.

US Pat. No. 11,111,278

USE OF A SMALL NATIVE PEPTIDE ACTIVATOR OF SERCA PUMP FOR TREATMENT OF HEART FAILURE AND OTHER DISORDERS CHARACTERIZED BY CYTOSOLIC CALCIUM OVERLOAD

The Board of Regents of t...


1. A polynucleotide, comprising a polynucleotide sequence encoding a Dwarf open reading frame (DWORF) consisting of SEQ ID NO: 3, operatively linked to a heterologous cardiac-specific promoter.
US Pat. No. 11,111,534

NUCLEIC ACID SAMPLE PREPARATION METHODS

Roche Sequencing Solution...


1. A method of preparing asymmetric nucleic acid templates for sequencing, the method comprising:(a) contacting a single-stranded sample nucleic acid with a first adaptor molecule comprising a single-stranded extendable primer region and a double-stranded hairpin region;
(b) ligating the hairpin region of the adaptor to the first end of the sample nucleic acid;
(c) extending the extendable primer region of the adaptor to copy the sample nucleic acid and form an extended nucleic acid having a single A 3? overhang of the extended strand, wherein the extended nucleic acid is a first complement to the sample nucleic acid;
(d) ligating a second adaptor to an end of the extended nucleic acid opposite of the hairpin end, the adaptor comprising a double-stranded duplex region having (i) a first overhang region comprising a single T 5? overhang, and (ii) a second overhang region comprising a primer site region, thereby forming an asymmetric nucleic acid template, and
(e) performing an open-fold replication whereby the asymmetric nucleic acid template having the hairpin at one end is opened to form a linear single-stranded molecule, and the linear single-stranded molecule is copied from a primer binding to the primer site region in the second adaptor to form a double-stranded molecule, wherein the double-stranded molecule comprises:the sample nucleic acid,
the first complement to the sample nucleic acid,
a complement to the first complement to the sample nucleic acid, and
a second complement to the sample nucleic acid.


US Pat. No. 11,111,279

NATO3 MUTANT POLYPEPTIDES AND USES THEREOF

GRAND VALLEY STATE UNIVER...


1. An isolated mutant Nato3 polypeptide, the polypeptide comprising at least one mutation in any one or more serine or threonine amino acid residues in the HLH domain defined by amino acids 99 to 158 of SEQ ID NO: 1, wherein the at least one mutation comprises a substitution of serine or threonine with either aspartic acid or glutamic acid.
US Pat. No. 11,111,535

PROBES, LIBRARIES AND KITS FOR ANALYSIS OF MIXTURES OF NUCLEIC ACIDS AND METHODS FOR CONSTRUCTING THE SAME

QIAGEN GmbH, Hilden (DE)...


1. A library of oligonucleotide probes, wherein each probe in the library comprises a recognition sequence tag and a detection moiety, wherein the recognition sequence tag has at least one modified monomer analogue that increases the binding affinity for the complementary target sequence relative to the corresponding unmodified oligodeoxyribonucleotide,wherein each probe has sufficient stability for sequence-specific binding and detection of its target sequence under stringent conditions,
wherein each probe has independently a total of 8 or 9 nucleotides,
wherein the library comprises a total of from 50 to 500 probes,
wherein the probes in the library hybridize to more than 90% of the mRNAs set forth in SEQ ID NOS: 47-35734, and
wherein at least one modified monomer analogue is a non-naturally occurring nucleotide analogue, a deoxyribose or ribose analogue, or an internucleotide linkage other than a phosphodiester linkage.

US Pat. No. 11,111,280

PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST SMALL CELL LUNG CANCER AND OTHER CANCERS


1. A method of eliciting an immune response in a patient who has cancer, comprising administering to said patient a population of activated T cells that selectively recognize cells that aberrantly present a peptide consisting of the amino acid sequence of SEQ ID NO: 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20,wherein the activated T cells are cytotoxic T cells produced by contacting T cells with an antigen presenting cell that presents the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell,
wherein said cancer is selected from the group consisting of lung cancer, melanoma, liver cancer, breast cancer, uterine cancer, Merkel cell carcinoma, pancreatic cancer, gallbladder cancer, bile duct cancer, colon or rectum cancer, urinary bladder cancer, kidney cancer, leukemia, ovarian cancer, esophageal cancer, brain cancer, gastric cancer, and prostate cancer.

US Pat. No. 11,111,536

METHOD FOR DETERMINING CROSS CONTAMINATION OF MOUSE GENES FOR HUMAN CELLS IN A PATIENT-DERIVED XENOGRAFT CELLS

ABION INC, Seoul (KR)


1. A method for determining cross contamination of mouse genes for human cells in a method for determining patient-derived xenograft cells, the method comprising the steps of:amplifying a human papola gene and a mouse papola gene using oligonucleotide primers consisting of base sequences of SEQ ID NOS: 5 to 8 by a PCR method;
hydrolyzing oligonucleotide probes consisting of base sequences of SEQ ID NOS: 11 and 12; and
detecting a labeling means binding to the probes and determining a ratio of the human papola gene and the mouse papola gene to determine cross contamination.

US Pat. No. 11,111,281

B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS


1. A method of treating a patient who has melanoma, wherein the cancer comprises cancer cells that overexpress the ZNF761, the ZNF765, the ZNF813, or the ZNF845 polypeptide and present at their surface in a complex with an MHC class I molecule a peptide consisting of the amino acid sequence of SEQ ID NO: 365, comprising administering to said patient a population of autologous activated cytotoxic T cells that bind the peptide consisting of the amino acid sequence of SEQ ID NO: 365 in the complex with the MHC class I molecule, and thereby target and kill the cancer cells.